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THE ROLE OF ESTROGEN SULFOTRANSFERASE IN HUMAN ADIPOGENESIS 
Chibueze A. Ihunnah, PhD 
University of Pittsburgh, 2014 
Estrogen Sulfotransferase (EST/SULT1E1) is a phase II conjugating enzyme which catalyzes the 
sulfonation of estrogen and estrogen like compounds. EST belongs to a large class of cytosolic 
sulfotransferases that are widespread in human and animal tissues, and facilitate sulfoconjugation 
through a donor co-substrate, 3′-phosphoadenosine 5′-phosphosulfate (PAPS). EST is an 
estrogen preferring sulfotransferase; among all human sulfotransferases it has the highest affinity 
for Estradiol (E2). 
The goal of this dissertation is to determine whether and how EST plays a role in human 
adipogenesis. Adipogenesis is the process whereby preadipocytes are stimulated to differentiate 
into functional mature adipocytes. The role of EST in adipogenesis has been studied in rodents, 
however in humans no studies have been published that address the role of EST in adipogenesis. 
In this dissertation we have uncovered a novel role for estrogen sulfotransferase in human 
adipogenesis. By using human primary adipose-derived stem cells (ASCs) and whole-fat tissues 
from the abdominal subcutaneous fat of obese and non-obese subjects, we showed that the 
expression of EST was low in preadipocytes but increased upon differentiation. Overexpression 
and knockdown of EST in ASCs promoted and inhibited differentiation, respectively. The pro-
adipogenic activity of EST in humans was opposite to the anti-adipogenic effect of the same 
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enzyme in rodents. Mechanistically, EST promoted adipogenesis by deactivating estrogens. The 
pro-adipogenic effect of EST can be recapitulated by using an estrogen receptor (ER) antagonist 
or ERα knockdown. In contrast, activation of ER in ASCs inhibited adipogenesis by decreasing 
the recruitment of the adipogenic peroxisome proliferator-activated receptor γ (PPARγ) onto its 
target gene promoters, whereas ER antagonism increased the recruitment of PPARγ to its target 
gene promoters. Linear regression analysis revealed a positive correlation between the 
expression of EST and body mass index (BMI), as well as a negative correlation between 
ERα expression and BMI. We conclude that EST is a pro-adipogenic factor which may serve as 
a druggable target to inhibit the turnover and accumulation of adipocytes in obese patients. 
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1.0  CHAPTER ONE: ESTROGEN SULFOTRANSFERASE/ SULT1E1 
1.1 INTRODUCTION 
Estrogen Sulfotransferase (EST/SULT1E1) is a phase II metabolic enzyme which catalyzes the 
sulfonation of estrogen and estrogen like compounds. The human EST gene is located on 
chromosome 4q13.2, and the EST protein consists of 294 amino acids [1]. EST belongs to a 
large class of cytosolic sulfotransferases that are widespread in human and animal tissues.  
facilitate sulfoconjugation through a donor co-substrate, 3′-phosphoadenosine 5′-phosphosulfate 
(PAPS), to a host of endogenous and exogenous compounds such as xenobiotic chemicals, 
pharmaceuticals, endogenous molecules such as fatty acids, steroids, and neurotransmitters [2, 
3]. Sulfonation plays an important role in the metabolism and biotransformation of the 
aforementioned substances in a number of ways including  increasing their water solubility and 
urinary excretion, bioactivation and bio-inactivation [4]. 
EST is an estrogen preferring sulfotransferase, among all human sulfotransferases it has the 
highest affinity for Estradiol (E2) and can also sulfonate estrone (E1). EST also has been shown 
to sulfonate catecholestrogens and 2-methoxyestradiol [2, 4-6]. The sulfoconjugation of E2 and 
other estrogens by EST deactivates the hormone, inhibiting its ability to bind to the estrogen 
receptor alpha or beta (ERα/β). Sulfation of estrogen is reversible by hydrolysis mediated by the 
cytosolic phosphatase Steroid Sulfatase (STS), creating an EST-STS regulated estrogen reservoir 
[5].   
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The regulation of estrogen is the primary function of EST, and the functional effects of this 
regulation are an integral part of normal mammalian metabolism. EST is expressed in a number 
of tissue including the mouse and bovine placenta, human mammary and endometrial epithelial 
cells, guinea pig adrenal gland, mouse uterus; mouse, rat and human testis [7-13]. EST largely 
regulates local tissue concentrations of estrogen, and it has been shown to be a potent protective 
enzyme against toxic estrogenic effects in peripheral tissues [14]. Dysregulation of EST has been 
shown to cause severe physiological consequences in the local tissue which it regulates.  In male 
mice the expression of EST maintains functional integrity of the epididymis by regulating 
luminal estrogen concentrations [3, 15]. It has been shown that EST is expressed abundantly in 
the reproductive tract, specifically in the epithelium of the epididymis (corpus and cauda), the 
vas deferens and small amounts in the prostate and seminal vesicle [15]. This is important 
because normal functioning of the epididymis is dependent on maintaining a specific ratio of 
androgen and estrogen activity; moreover it has been shown that sperm motility is greatly 
reduced in EST knockout mice, compared with wild-type controls [15]. Additionally, estrogen 
challenge in wild type mice that underwent epididymal ligation also showed marked reductions 
in sperm quality and motility [15]. These results demonstrate a specific role for EST in the 
epididymis in reducing local estrogen level and activity.   
In human umbilical vein endothelial cells, EST has been shown to regulate the inflammatory 
response and lipid metabolism [16]. Specifically in the presence of exogenous estrogen, loss of 
EST using siRNA caused decreased expression of anti-inflammatory cytokines, while pro-
inflammatory cytokines were upregulated; moreover PPARγ expression and the expression of its 
target genes involved in cholesterol metabolism were downregulated, including LDL-R, APO B 
and FASN [16]. SULT1E1 also plays a role in cancer susceptibility. It has been well established 
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that estrogens are an integral mediator in hormone dependent cancer. In several cohorts of 
female patients, mutations in the SULT1E1 gene caused decreased EST expression in 
endometrial, ovarian and breast cancer tissue and is associated with poor survival and 
reoccurrence of malignant tissue [1, 14, 17].  
The functional role of Est in the adipogenesis has been studied in animal models, however the 
overall functional impact is still controversial. Several in vivo and in vitro studies have shown 
that in female murine models Est acts a negative regulator of adipogenesis [3, 18]; aP2-Est 
transgenic mice over-expressing Est in adipocytes have decreased adipocyte size and improved 
hepatic insulin sensitivity, but reduced adipose tissue glucose uptake [18]. While other in vivo 
murine models have shown that the induction of Est is associated with hepatic insulin resistance, 
moreover ablation of Est was shown to improve metabolic function in female mice which 
includes increased energy expenditure, insulin sensitivity, and body composition [19].  
Mechanistically, the improved metabolic function was attenuated after ovariectomy which 
suggests that the metabolic benefit was mediated by increased estrogenic activity in the liver 
[19]. 
In humans no studies have been published that address the role of EST in adipogenesis.  
Recently it was reported that EST is expressed in the subcutaneous adipose tissue of  obese 
patients suffering from metabolic syndrome; additionally that same study reported that a positive 
correlation was found between the expression of EST and inflammatory cytokine signaling in 
adipose tissue [20]. Our study sought to examine the functional role of EST in human adipose 
tissue during adipogenesis.  
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1.2 NUCLEAR RECEPTOR DEPENDENT ROLE IN ADIPOSE TISSUE 
DEVELOPMENT 
1.2.1 Peroxisome Proliferator Gamma (PPARγ) 
Peroxisome Proliferator Gamma (PPARγ, NRIC3) belongs to the PPAR subfamily, which is part 
of the nuclear receptor superfamily of ligand activated transcription factors [21]. PPARγ is 
expressed in a number of tissue types, but its expression is highest in brown and white adipose 
tissue [21-23]. It is known for its role in lipid metabolism and glucose tolerance, and its 
dysregulation leads to a number of pathologies including hyperlipidemia, insulin resistance, and 
coronary artery disease[24]. PPAR gamma is activated by a number of lipid molecules including 
polyunsaturated fatty acids, nitrated unsaturated fatty acids and eicosanoids [25, 26].  
Additionally, PPARγ is the target for the thiazolidinedione (TZD) class of fibrate anti-diabetic 
drugs [24, 27, 28].  
Like many nuclear receptors, activation of PPARγ causes its translocation to the nucleus and 
heterodimerization with the Retinoid X Receptor (RXR), which increases its affinity for DNA. 
The PPARγ -RXR heterodimer binds to a short stretch of DNA called the PPAR response 
Element (PPRE) located in the proximal or distal promoter region of its targets genes. In order 
for transcription of its target genes to begin, the appropriate coactivators must also form a 
complex with PPARγ; these coactivators possess histone acetyltransferase activity and other 
chromatin remodeling properties [21, 24, 29].   
PPARγ has been well established as the most important transcription factor induced during the 
process of adipogenesis. In some fibroblast models activation of PPARγ alone is sufficient to 
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induce adipogenesis, while loss of function models in vivo and in vitro show that adipocytes 
cannot develop without PPARγ signaling; additionally PPARγ null mice die during 
embryogenesis. In humans, rare mutations in the DNA and ligand binding domain of PPARγ 
cause severe lipodystrophy and insulin resistance in these patients [30, 31].  
PPARγ functions in adipogenesis as part of a spatial and temporal cascade of transcription 
factors and enzymes that facilitate the proper development and maintenance of each adipocyte 
[23]. During differentiation mitogenic and adipogenic cues activate several members of the 
CAAT/ Enhancer Binding Protein family(C/EBP); (Covered more extensively in section 1.2.3) 
specifically C/EBPβ and C/EBPδ work in tandem to promote the activation of PPARγ by 
directly binding to the promoter region of PPARγ [29, 32].  Once PPARγ has been induced and 
activated by a ligand it can then induce C/EBPα, which further induces PPARγ in a positive 
feedback loop; PPARγ can then bind the promoter regions of its target genes including Fatty 
Acid Binding Protein 4(FABP4)/ Adipocyte factor 2(aP2), Lipoprotein Lipase (LPL),  and the 
Glucose Transporter 4 (GLUT4)[21, 24, 27, 33, 34]. LPL and aP2 are classic markers of 
adipogenesis, LPL serves as a dual action triglyceride hydrolase as well as bridging factor for 
membrane receptor mediated lipoprotein uptake; while aP2 serves a potent intracellular 
transporter that controls metabolism of long and short chain fatty acids as well as other 
hydrophobic ligands [35, 36]. Throughout this document, these genes (LPL, aP2, C/EBPα) will 
be used to measure the extent of PPARγ activation and adipogenesis in various conditions.  
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1.2.2 Estrogen Receptor Alpha/Beta (ERα/β) 
The Estrogen Receptor alpha and beta (ERα/β) are part of the nuclear receptor superfamily of 
ligand activated transcription factors (NR3A1 and NR3A2 respectively)[37]. Once activated by 
the appropriate ligand, these receptors undergo a conformational change in the LBD that 
promotes dissociation from corepressor proteins, cytosolic heat shock proteins, chaperone 
proteins and cochaperone proteins [38, 39]. The ER is then shuttled into the nucleus, can 
homodimerize and bind to short stretches of DNA called estrogen response elements (ERE), 
which are located in the promoter region of their target genes [40]. In order for the ERs to elicit 
transcriptional activation, a complex of coregulators must also bind to the receptor at distinct 
Leucine rich motifs (LeuXxxXxxLeuLeu, LXXLL) [41]. The coregulators that activate 
transcription are known as coactivators; they possess histone and chromatin remodeling 
capabilities that allow the circumvention of repressive chromatin features and subsequent 
activation of gene transcription through general transcription machinery [41, 42].  
ERα/β is expressed in male and female subcutaneous preadipocytes and adipocytes as well as in 
visceral adipose tissue, rendering these tissues amenable to changes caused by estrogen signaling 
[40, 43]. This expression has been found in several other species including mice, rats, and sheep 
as well [40]. Hormone signaling plays a major role in adipose tissue development, maintenance, 
and apoptosis. In addition to other critical hormones involved in adipogenesis such growth 
hormone, thyroid hormone and glucocorticoids; sex hormones also play an integral role in 
adipose tissue development, and often lead to sexually dimorphic manifestations of adipocyte 
size, number, depot location, and life cycle [44-47]. Men tend to have a central/abdominal 
deposition of adipose tissue, whereas females accumulate adipose tissue in the gluteal and 
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femoral regions [46-50]. Epidemiologic evidence shows that menopause typically leads to a 
central distribution of adipose tissue, demonstrating the effects sex hormones, and in particular 
estrogen, have on adipose tissue development and distribution [51-54]. The mechanisms 
delineating the sexually dimorphic effects of hormone signaling on adipose tissue development 
are not entirely clear; subcutaneous adipose tissue has a higher concentration of estrogen and 
progesterone receptors compared to visceral adipose tissue, which has a higher concentration of 
the androgen receptor [44]. Evidence also suggests that changes in eating and energy expenditure 
are partly the cause[44, 47];  however a large body of evidence from studies in mice suggests 
that these differences are due to genetic and transcriptional changes that effect the expression of 
key proteins involved in adipogenesis [54-56].  
In subcutaneous adipose tissue ERα  and ERβ are both expressed, however ERα activation has 
been shown to effect energy homeostasis and mediate estradiol’s genomic effects on body 
weight and adipogenesis [44]. There are several known anti-adipogenic genomic effects found 
after estradiol treatment such as reductions in Lipoprotein Lipase concentration (LPL), as well as 
reduced expression of the Sterol Regulatory Element-Binding Protein (SREBP1c) [40, 54]. LPL 
is a PPARγ target gene  and  an important enzyme expressed during adipogenesis [21]; SREBP1c 
is an important transcription factor that enhances lipogenesis mainly through the up-regulation of 
its lipogenic target genes [40]. LPL and SREBP1c both contain an ERE in their promoter region, 
which suggests that ERα can directly inhibit the transcription of said genes, culminating in a 
reduction of adipogenesis and lipogenesis [40, 57, 58].  
The genomic effects mediated by estrogen signaling lead to significant functional changes in 
adipose tissue accumulation and distribution. Several studies have shown that loss of estrogen 
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signaling in mice, either through genetic knockout of the ERα receptor, genetic knockout of 
aromatase, or through ovariectomy lead to a significant increase in adiposity [43, 44, 55]. In 
humans, it is well documented that post- menopausal women tend to accumulate adipose tissue 
in the abdominal region, however this can be reversed by estrogen replacement therapy [40, 59]. 
Men lacking aromatase/CYP19A1, a member of the cytochrome P450 family that catalyzes the 
aromatization of androgens and converts them to estrogens, have increased body fat, insulin 
resistance and Type II diabetes, which can also be reversed by estrogen treatment [40, 60, 61].   
1.2.3 CCAAT Enhancer Binding Protein Family C/EBP family 
The CCAAT binding protein (C/EBP) family of transcription factors is aptly named based on the 
short stretch of DNA that it binds in the promoter regions of its target genes. This family of 
proteins is made of several major isoforms, C/EBP alpha, beta, delta, gamma and epsilon [62, 
63]. Each of the members of this family contain a conserved basic leucine zipper (bzip) DNA 
binding domain that promotes the binding of said transcription factors to the CCAAT motif [24, 
64]. In contrast, these transcription factors share very little sequence homology in the N-terminal 
region of the protein which house transrepression and transactivation domains [65]. The C/EBP 
proteins are expressed in the nucleus of most cell types of the body and are involved in an array 
of functions including  cell cycle regulation,  body weight homeostasis, immune and 
inflammatory responses, macrophage and adipose tissue differentiation [62, 63, 65-72].  
In adipose tissue differentiation  C/EBPβ/δ/α display distinct temporal and spatial expression 
patterns which  regulate adipose tissue development and maintenance [64].  Specifically, these 
proteins play a critical role in the induction of PPARγ and many PPARγ target genes. It has been 
demonstrated in vivo and in vitro that during the initiation of adipogenesis, C/EBPβ and C/EBPδ 
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form hetero/homodimers that promote the expression of PPARγ through direct interaction with 
the distal enhancer region of the PPARγ promoter [32, 73]. Once PPARγ is activated it then 
promotes the expression of C/EBPα, which further enhances the expression of PPARγ itself by 
binding to a CCAAT motif in the PPARγ distal promoter [32, 34, 73]. This positive feedback 
loop is important because many of PPARγ’s target gene promoters also contain CCAAT motifs 
in their distal promoter regions; C/EBPα binds to these motifs and enhances the expression of 
adipogenic genes such as LPL, aP2, PEPCK, and GLUT4 [21, 32, 73]. Additionally, the 
expression of C/EBPα is critical to maintain insulin sensitivity; it has been shown that the 
activation of PPARγ in C/EBPα-deficient cells leads to abnormally low insulin sensitivity. 
Several other papers have confirmed that C/EBPα contributes to the full adipose program beyond 
simply maintaining PPARγ and PPARγ target gene expression [21, 74].    
 
Figure 1. C/EBP Family Induction of Adipogenic Genes. Adopted from :  Lefterova, M.I. and 
M.A. Lazar, New developments in adipogenesis. Trends Endocrinol Metab, 2009. 20(3): p. 107-
14. [24].  C/EBPβ and δ bind to their response element early, also C/EBPα and PPARγ binding 
to its PPRE mid/late during adipogenesis. 
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1.2.4   Nuclear Receptors and Coregulators in Nuclear Receptor Pharmacology  
The nuclear receptor (NR) superfamily is made up of 49 ligand activated transcription factors 
which share considerable structural similarity. These receptors mediate the response of steroids, 
retinoids, fatty acids, thyroid hormones, and pharmaceuticals to regulate endo-and xenobiotic 
metabolism, as well as a host of physiological processes [75].   Nuclear receptors are modular 
proteins that contain the following domains; the N-Terminal (A-B) domain which contains the 
Activation Factor-1(AF-1) transactivation domain  that is activate independent of ligand binding, 
the (C) domain which contains the DNA binding domain which is comprised of two zinc fingers 
which recognizes short conserved DNA motifs, the (D) domain which is a flexible hinge region, 
the (E) domain which contains the ligand binding domain, and the C-Terminal  (F) domain 
which contains the Activation Factor-2 domain (AF-2) is a ligand dependent activation 
domain[41, 75, 76].  
 
Figure 2. Modular Structure of Nuclear Receptors.  
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A general model of nuclear receptor signaling is that in the absence of ligand NRs remain 
sequestered in the cytosol by corepressors, heat shock proteins , chaperone proteins, and 
cochaperone proteins [41, 75]. Additionally, these repressor proteins promote an inactive 
conformation in the LBD that decreases the affinity of the NR for coactivators and its cognate 
DNA response element [38]. Ligand binding causes a conformational change in the LBD that 
enhances the binding affinity of the AF2 region and LBD with specific amino acid motifs found 
in coactivators [77, 78]. Nuclear receptor coactivators contain an “NR box” sequence, a leucine 
rich stretch of amino acids, LXXLL, or sometimes FXXLF [41, 77]. An array of nuclear 
receptors contain single or multiple copies of the NR box which dictates the specificity and 
affinity of each NR for certain coactivators [41].  The recognition of this sequence by various 
nuclear receptors is based on hydrophobic interactions and hydrogen bonding between specific 
charged amino acid residues that make up the LBD [79].  A “charge clamp” is formed by a 
lysine residue in helix 3 and a glutamic acid residue in helix 12 that clamp the NR box α-helix in 
place by forming hydrogen bonds with the LXXLL coactivator motif [79].   This motif has been 
shown to facilitate direct binding of coactivators to nuclear receptors, however only about half of 
all coactivators contain this motif but they are still able to bind and activate nuclear receptors 
[41]. 
The recruitment of coactivators can enhance the ability of nuclear receptors to bind to their 
specific DNA motif known as a hormone response element (HRE)[41, 80].  Coactivators 
enhance transcriptional activation in a number of ways; many contain methyltransferase and 
acetyltransferase activity which is essential for chromatin and histone remodeling [80].  In 
addition to enzymatic properties, coactivators can act as scaffolding proteins or also convey post 
translational modifications (PTMs) that act on nuclear receptors and other coactivators [77]. 
11 
 
These PTMs can enhance DNA binding and stabilize the transcription complex involved in 
initiation, elongation, and termination [41, 42, 77, 81]. Common coactivator PTMs include 
methylation, acetylation, phosphorylation, sumoylation, and ubiquitination[41].  To date over 
300 different coactivators have been identified and can affect a host of cellular processes [42]. 
Some of the most studied coactivators include the steroid receptor coactivator family (SRC) 
which includes SRC-1, 2, and 3. SRCs are recruited to NRs early during transcription because 
they serve as scaffolding proteins for other coactivators and transcriptional machinery to bind 
[42]. Other important coactivators include CREB binding Protein (CBP), which possesses 
histone acetylase activity and  PPARγ co-activator-1a (PGC-1a) which utilizes both 
phosphorylation and acetylation to regulate NR activity [81]. 
In addition to coactivator binding that enhances NR activation, corepressors are also a class of 
coregulators that can bind to NRs and alter chromatin structure towards an inactive state. These 
proteins can recruit histone deacetylases, increase nuclear export, and promote cytoplasmic 
sequestration of their target NRs [42]. Some of the most well studied corepressors include 
nuclear corepressor 1/ 2 (NCoR 1 and 2) which use phosphorylation to increase NR nuclear 
export, as well as SHARP which uses phosphorylation to increase transcriptional repression of 
its NR targets [81, 82].  
The concentration, activity, and affinity of coactivators for nuclear receptors are largely cell 
dependent and are subject to temporal and spatial changes [83]. Additionally, many nuclear 
receptors share the same coactivators, therefore competition known as “squelching” or  
“crosstalk” can occur [41]. This phenomenon can occur naturally when the activation of one 
nuclear receptor by its ligand inhibits the transcriptional pathway controlled by another nuclear 
receptor that shares the same coactivator(s) [41, 84-87]. Crosstalk between nuclear receptors can 
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have significant effects on cell growth, proliferation, and differentiation; sometimes leading to 
dysregulation of critical metabolic processes [87, 88].  
The importance of coregulator function at the molecular level is exemplified by the array of 
clinical pathologies that manifest from loss or perturbation of coactivator or corepressor 
signaling. These diseases include but are not limited to Rubinstein-Taybi Syndrome( RTS),  
Androgen Insensitivity Syndrome(AIS), breast cancer, prostate cancer, Huntington’s Disease, 
and Refetoff Syndrome [89].  RTS is an autosomal dominant inherited disease that is clinically 
characterized by mental retardation, webbed fingers and toes, pulmonary stenosis, chest  
abnormalities, vertebral anomalies and sleep apnea [90]. Individuals with RTS possess genomic 
mutations in the CREB Binding Protein (CBP) gene or complete deletion of said gene. This 
mutation is  so striking because CBP is an extremely important coactivator that can facilitate the 
activation of several nuclear receptors including the estrogen receptor, thyroid hormone receptor, 
retinoic acid receptor, glucocorticoid receptor and the vitamin D receptor [90]. Androgen 
Insensitivity Syndrome is an X-linked recessive disorder that affects males with a karyotype of 
46XY but have end-organ androgen insensitivity due to mutations in the androgen receptor (AR) 
gene and signaling pathway[91].  AIS patients often have a common mutation in the AR that is 
located in the AF-1 domain of the receptor, impairing its ability to interact with coactivators 
[89].  Patients with breast cancer tend to have increased expression and activation of the 
coactivator AIB1 which increases the recruitment of CBP/p300 and Cyclin D to the estrogen 
receptor [89, 92]. This facilitates increased trans-activation of the ER and also increased 
signaling to the tumor.  Similar mechanisms have been found in prostate cancer patients where 
increased expression and activation of SRC-1 or TIF2 promotes the transactivation of Cyclin E 
and the AR[89].  Finally, in patients with Refetoff Syndrome, also known as Resistance to 
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Thyroid Hormone (RTH), the Thyroid Receptor β disproportionally recruits the corepressor 
nuclear corepressor 1/2 (NCoR1 or NCoR2) in lieu of coactivator SRC-1[89]. This inhibits TR 
signaling, and elevates circulating levels of thyroid hormone (T3) and thyroid stimulating 
hormone (TSH) [92].  Taken together, the trans-activation or repression of a host of nuclear 
receptors by coregulators is an essential molecular mechanism that can have severe and 
significant consequences if attenuated or abated.  
 
 
Figure 3 Nuclear Receptor Activation is Facilitated by Coactivators 
Coactivators such as SRC1 and CBP contain DNA modifying enzymes such as Histone 
Acetyltransferase (HAT) that enhance the recruitment of NR’s to their DNA response elements 
and enhance transcriptional activation of NR target genes. Ac, Acetyl group; NR; Nuclear 
Receptor; HRE, Hormone Response Element; CBP, CREB Binding Protein; SRC1, Steroid 
Receptor Coactivator.   
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2.0  CHAPTER II:  A PRO-ADIPOGENIC ROLE FOR EST IN HUMAN 
ADIPOGENESIS AND LIPOGENESIS 
 
2.1 BACKGROUND: MOLECULAR MECHANISM CONTROLLING ADIPOGENESIS 
AND LIPOGENESIS 
Adipogenesis is the process whereby preadipocytes are stimulated to differentiate into functional 
mature adipocytes. Adipocytes make up the majority of  white adipose tissue (WAT) and brown 
adipose tissue (BAT); however adipose tissue also contains preadipocytes, macrophages and 
other immune cells, fibroblasts, and stromal vascular cells [93]. This study focuses on the 
differentiation of WAT; however BAT is also important for body weight homeostasis, energy 
metabolism, and thermogenesis.  BAT is found in newborn and adult humans, as well as many 
mammals albeit this type of adipose tissue is not as abundant as WAT [94]. It contains a large 
amount of mitochondria that utilize several isoforms of Uncoupling Protein (UCP) to generate 
heat from stored lipids [95]. WAT was once thought of as only a lipid storing compartment, 
adipose tissue is now regarded as a critical component of the endocrine system with 
paracrine/autocrine signaling capabilities [64]. Adipose tissue contains connective tissue, nerve 
tissue, stromal vascular cells and immune cells [96]. Functionally, WAT can regulate food intake 
and energy expenditure by responding to afferent signals to mobilize fat stores for energy and 
also by expressing and secreting factors with endocrine function on other organs and the CNS 
[64, 97]. Interestingly, because adipose tissue is an amalgamation of an array of different tissue 
and cells types, many of the secreted factors actually are not derived from the adipocyte fraction 
[98].  Some of the secreted factors include cytokines and cytokine related proteins such as leptin, 
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TNFα, and Interleukin 6 (IL6).  This class of proteins can regulate food intake, satiety, and the 
release of insulin from the pancreas (Leptin); others such as IL6 and TNFα are secreted by 
macrophages found in adipose tissue and are positively correlated with obesity, insulin 
resistance, and impaired glucose tolerance [93]. Adipose tissue also secretes proteins such as 
adiponectin which can enhance insulin sensitivity and fatty acid oxidation in the liver and 
muscle, as well as decrease the adhesion of macrophages and subsequent formation of foam cells 
on the vascular wall [93, 99].  Other proteins secreted by adipose tissue include those involved in 
fatty acid metabolism and transport such as Lipoprotein Lipase (LPL), Cholesterol Ester Transfer 
Protein (CPT), and  Apolipoprotein E (APO- E); and proteins involved in steroid metabolism 
such as Aromatase, 17β hydroxysteroid dehydrogenase (17β HSD), as well as 11β 
hydroxysteroid dehydrogenase 1 ( 11β HSD1) [93].  Additionally, adipose tissue expresses an 
array of receptors which allow them to respond to afferent signaling and secrete the assortment 
of the aforementioned proteins. Some of these include traditional hormone receptors such as 
insulin, glucagon, Growth Hormone (GH), Thyroid Stimulating hormone (TSH), and 
Angiotensin II Receptors [93]. Adipose tissue also expresses a host of nuclear receptors which 
include the Glucocorticoid, Thyroid, Estrogen, Androgen, Progesterone, and Vitamin D Receptor 
[93]. Finally, adipose tissue also expresses cytokine and catecholamine receptors such as Leptin, 
IL6, TNFα, β1, β2, β3, and α1/2 adrenergic receptors [93].   
Preadipocytes originate from multipotent mesenchymal stems cells (MSC) of the mesodermic 
embryonic germ layer located in various fat depots in the body (abdominal, back, thigh etc.) 
[100]; based on their origin, MSC have the ability to differentiate into mature cells of the 
mesodermic lineage including adipocytes, myocytes, chondrocytes, and osteocytes [97, 100]. 
WAT development begins before birth and expansion of adipocyte number continues throughout 
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adolescence until a tightly controlled “set point” has been reached by young adulthood [101-
103]; recently it has been reported that in adult humans there is approximately a 10% annual 
turnover of adipocytes to maintain the individual’s “set point” [101, 103].  
The process of differentiation /adipogenesis is a highly conserved and controlled event that has 
been studied extensively, albeit mostly in animal models, but recently in human cell culture and 
in vivo models also. Adipogenesis is characterized by the induction and repression of adipocyte 
specific genes that morphologically and biochemically transform preadipocytes to functionally 
mature adipocytes. The induction of adipogenesis begins with the “commitment” of MSC to the 
adipocyte lineage [100];  the commitment process is not well characterized but it has been 
suggested that this process may involve promoter hyper-and hypomethylation patterns in genes 
which facilitate adipogenesis [104, 105]. Commitment is stimulated in vivo by increased energy 
intake and elevated glucose uptake over time [106], as well changes in hormones such as insulin, 
estrogens, androgens, thyroid hormone, and IGF-1 [44-47].  This can be recapitulated in vitro by 
culturing preadipocytes with media enriched with insulin, dexamethasone, and 3-isobutyl-1-
methylxanthine (IBMX)[29, 107]. Once cells have been committed, they undergo one final 
round of clonal expansion followed by growth arrest [100].  Molecularly, the first transcription 
factors activated are C/EBPβ and C/EBPδ [29, 108, 109]; these transcription factors are activated 
by Krüppel-like factors (KLFs) , and phosphorylated by CREB binding protein(CBP),  Glycogen 
Synthase Kinase -3β (GSK3β), which primes them to bind to their appropriate DNA motifs in 
the PPARγ distal promoter [24, 100]. PPARγ then binds to its PPRE in the C/EBPα distal 
promoter and induces its expression, this also leads to activation of a positive feedback loop 
between PPARγ and C/EBPα, thus potentiating the expression of each transcription factor [21, 
110-112].  PPARγ and C/EBPα induce the expression of PPARγ target genes involved in 
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lipogenesis and adipogenesis such as Lipoprotein Lipase, Fatty Acid Binding Protein 
(FABP4)/Adipocyte Protein-2(aP2), Glucose Transporter 4 (GLUT4), Phosphoenolpyruvate 
Carboxykinase 2 (PEPCK), CD36, Perilipin(PLIN1),  and others [21, 108]. C/EBPα also is 
necessary for proper insulin sensitivity; cells lacking C/EBPα are not responsive to insulin 
stimulation, however this can be reversed once C/EBPα  is ectopically expressed [29]. The 
increased insulin sensitivity mediated by C/EBPα helps to promote the expression of the sterol 
regulatory element-binding protein 1c (SREBP) which is essential for proper induction of 
lipogenic genes [100, 113].  SREBP1c (mouse homolog ADD1) is part of a family of helix-loop-
helix-leucine zipper proteins that modulate cholesterol metabolism and lipogenesis. The 
induction of SREBP1c is not directly promoted by PPARγ, however the expression of SREBP1c 
begins shortly after the expression of PPARγ and CEBPα [114].  SREBP1c is activated by 
insulin signaling through the PI3K-AKT signaling pathway[115, 116],  which facilitates binding 
to the sterol regulatory element (SRE) or “E-Box” motif found in the promoter region of its 
target genes which include  fatty acid synthase (FASN/FAS), acetyl CoA Carboxylase (ACC),  
and stearoyl-CoA desaturase (SCD1) [64, 114].  
Adipogenesis is a dynamic process, where many environmental cues, transcription factors, 
enzymes, hormones and signaling molecules influence the induction or inhibition of this process. 
It has been studied extensively in mice and humans; however, the role that EST plays in 
adipogenesis is unknown.  Our study sought to examine the functional role of EST in human 
adipose tissue and specifically adipogenesis. The primary function of EST is to modulate 
estrogen signaling. Estrogen and other sex hormones play a major role in adipose tissue signaling 
and maintenance, as well as a critical role in adipogenesis. Based on our studies done in animals 
and our preliminary data, we hypothesize that EST can enhance the induction of adipogenesis 
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through its repressive effects on estrogen signaling.  Many factors regulate the overall process 
of adipogenesis however, the major focus of this study is to analyze the genomic effects that 
over-expression or knockdown of EST has on the critical transcriptional regulators that mediate 
the induction of adipogenesis and lipogenesis. In this document we will focus on the affect EST 
has on PPARγ, and its target genes LPL, aP2 and the C/EBP family including C/EBP α, β, and δ. 
Additionally, since adipogenesis and lipogenesis are not mutually exclusive, we will also analyze 
the key transcription factors involved in the induction of lipogenesis, specifically SREBP1c  and 
its target genes ACC, FASN, and SCD1.  Functionally, we can measure the overall outcome of 
the genomic changes in adipogenic signaling by quantitatively and qualitatively analyzing lipid 
droplet formation in our adipocytes.  We will use these and other techniques to demonstrate the 
role EST plays in human adipogenesis.  
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Figure 4. Adipogenic Transcriptional Cascade. Figure adopted from:   Tang, Q.Q. and M.D. 
Lane, Adipogenesis: from stem cell to adipocyte. Annu Rev Biochem, 2012. 81: p. 715-36 [100] 
DEX, Dexamethasone; PKA, Protein Kinase A; GSK, glycogen synthase Kinase.  
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2.2 METHODS 
2.2.1 Patient Population 
ASC and adipose tissue collection:  Human adipose-derived stem cells (ASCs; primary 
preadipocytes) and whole fat/lipoaspirate were obtained through the Adipose Stem Cell Center, 
Department of Plastic Surgery, University of Pittsburgh. The whole fat or liposuction aspirates 
were collected from the abdominal subcutaneous fat of 18 female patients who were non-diabetic 
nonsmokers and ranged in age from 32 to 59 years. Subsequently, preadipocytes were isolated 
from the abdominal subcutaneous fat of these 18 patients [15 obese patients and 3 nonobese 
(lean) patients]. For linear regression analysis, 16 additional obese patients’ whole fat or 
lipoaspirate was analyzed. All experiments were performed on cells from the obese patients 
except as otherwise specified. The names of the patients were kept anonymous, and all patients 
used for preadipocyte differentiation experiments were female, non-diabetic nonsmokers and 
ranged in age from 25 to 56 years. The cells were cultured under standard conditions as reported 
previously. Briefly, cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F-12 
medium containing 10% standard fetal bovine serum (FBS) and 1% penicillin-streptomycin 
(Pen-Strep). Each cell line was cultured for no more than four passages. Patient 
sample and data collection were performed in accordance with the University of Pittsburgh 
Institutional Review Board Protocol PRO12050016. A complete list of patients used for 
preadipocytes and whole fat/ liposuction studies can be found in APPENDIX A.  
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2.2.2 Generation of pCMXpl2 EST  
Human EST was cloned using cDNA synthesized from total RNA isolated from differentiated 
human adipocytes. In short, 1ug of total RNA was aliquoted for cDNA synthesis using the Iscript 
reverse transcriptase kit.  For PCR amplification of the EST coding sequence, primers were 
designed to amplify the full length EST coding sequence with the HINDIII restriction enzyme 
sequence flanking the 5’ region (forward primer) and the NHEI restriction enzyme sequence 
flanking the 3’ region (reverse primer).  This design allowed us to sub-clone the EST coding 
sequence into the pCMXpl2 expression vector. The pCMXpl2 expression vector and the EST 
PCR product were digested overnight with HINDIII and NHEI restriction enzymes and gel 
purified in 1% agarose. Ligation was carried out using T4 DNA ligase at 16° C overnight to 
produce the pCMXpl2-hEST construct. Ligation products were transformed into JM109 bacterial 
cells by electroporation and plated overnight on ampicillin-agarose plate. Clones were screened 
using mini-preps to isolate plasmid DNA.  Successful clones were confirmed by digesting the 
purified pCMXpl2-hEST plasmids with HINDIII and NHEI restriction enzymes to release the 
SULT1E1 fragment from the vector (Fig 5). For final confirmation of successful cloning, we 
used primers against the CMV promoter to sequence the purified vector through the University 
of Pittsburgh Genomics Core.  Results can be found in Appendix A. Functional analysis was 
validated using a transfection and reporter gene assay in which the estrogen deactivating activity 
of EST was demonstrated (Fig 6).   
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 Figure 5.  pCMXpl2- hEST cloning confirmation  
10 Clones were isolated from ampicillin-agarose plates and plasmid DNA was purified  using 
mini-preps. Clones were digested with HINDIII and NHEI restriction enzymes overnight to 
release EST coding sequence (CDS) from the plasmid backbone. The results show that 9 out of 
10 clones isolated successfully incorporated the EST CDS. One clone was used for functional 
testing and virus production.  
 
 
Figure 6.  Functional Analysis to confirm EST Activity. 
 tk-ERE-Luc (where ERE is estrogen response element Luc is luciferase) and  pCMX-ERα  were 
transfected in triplicate using 293T cells. pCMX-EST was transfected and  inhibited the E2 
induced ERα activation.  pCMX–β-Gal (where β-Gal  is β-galactosidase), was used to normalize 
the luciferase signal. Estrogen treatment concentration was 10nM. .  P < .05*, P < .01**, P < 
.0001***. 
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2.2.3 Site Directed Mutagenesis for the Creation of EST-AAK mutant  
3’ phosphoadenosine 5’phosphosulfate (PAPS) is the co-substrate and source of the sulfonate 
group in the sulfonation reaction catalyzed by SULT1E1 [117].  We along with others have 
reported that by mutating a conserved domain in the P-loop region of the PAPS-binding domain 
from GxxGxxK (GGK) to AxxAxxK(AAK), the enzymatic activity of EST was completely 
abolished [3, 118]. To produce an enzymatically dead SULT1E1 virus, we used the PCR based 
overlap extension method [119]. The PCR product was cloned into a pCMXpl2 expression 
vector using the restriction enzyme sites HINDIII and NHEI to produce pCMXpl2-AAK-hEST. 
To confirm the AAK-EST coding sequence and orientation were correct we sequenced the 
purified plasmid through the University of Pittsburgh Genomics Core. Results can be found in 
Appendix A.  The lack of enzymatic activity of the EST AAK mutant was validated in a 
transfection and reporter gene assay in which the estrogen-deactivating activity of wild-type EST 
was abolished in cells transfected with a virus expressing the EST AAK mutant (Fig 7).  
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 Figure 7 . Functional Analysis to Confirm Loss of Enzymatic Activity in AAK-EST. 
(A) tk-ERE-Luc (where ERE is estrogen response element Luc is luciferase) and  pCMX-ERα  
were transfected in triplicate using 293T cells. pCMX-EST was transfected and  inhibited the E2 
induced ERα activation, but pCMX-AAK was unable to inhibit E2 induction  of luciferase .  
pCMX–β-Gal (where β-Gal  is β−galactosidase), was used to normalize the luciferase signal. 
Estrogen treatment concentration was 10nM.  P < .05*, P < .01**, P < .0001***.   
 
2.2.4 Creation and Characterization of Lentivirus to Over-express EST and AAK- EST 
To produce lentivirus expressing EST, the full length coding region was PCR amplified from the 
pCMXpl2- hEST plasmid using primers that incorporated the PMEI restriction enzyme sites 
flanking the 5’ and 3’ regions of the SULT1E1 coding sequence. EST was then sub-cloned into 
the pWPI lentiviral expression vector via the PMEI restriction sites to produce pWPI-EST. To 
confirm the coding sequence and orientation were correct, we used primers against the 
EF1α promoter to sequence the purified plasmid through the University of Pittsburgh Genomics 
Core. Results can be found in Appendix A.  
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Lentiviral particles were generated using the second-generation system that contained three 
plasmids: the transgene expression plasmid (pWPI or pWPI-EST), a packaging plasmid 
(psPAX2), and an envelope plasmid (pMDG.2). All three plasmids were transfected 
simultaneously into 293T cells for viral particle packaging, assembly, and amplification using 
Trans-IT transfection reagent from Mirus (Madison, WI). Viral lysates were collected every 24 h 
after transfection, filtered with 0.45-um-poresize Millex GV syringe filter units from Millipore 
(Billerica, MA), pooled, and concentrated with a Lenti-X-Concentrator from Clontech (Mountain 
View, CA). Titer concentrations were assessed with Lenti-X-Stix from Clontech and by 
fluorescent examination of the green fluorescence protein that was engineered in the lentiviral 
vector. Viral lysates were aliquoted and stored at -80°C until use.  
AAK Mutant Virus 
 We used PCR to amplify AAK-hEST from the pCMXpl2-AAK-hEST plasmid discussed in 
section 2.2.3.  The amplification incorporated the PMEI restriction enzyme sites flanking the 5’ 
and 3’ region of the coding sequence.  The PCR product was then sub-cloned into pWPI using 
the PMEI restriction sites. Lentiviral particles were generated using the second generation 
lentiviral system as described previously.                     
2.2.5 Creation and Characterization of Lentivirus to Knockdown EST  
To generate lentivirus expressing short hairpin RNAs (shRNAs) against EST (shEST), 
expression plasmids containing shEST were purchased from Open Biosystems (Pittsburgh, PA). 
For each knockdown, five sequences were purchased and tested in transient-transfection assays. 
In this assay 0.2ug pCMX-EST was transfected into 293T cells, followed by 2ug of one of the 5 
plasmids purchased (10:1 knockdown constructs: pCMX-EST); the sequence with the most 
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efficient knockdown was chosen for lentiviral production (Fig 8). A scrambled shRNA (shSCR) 
plasmid was purchased to serve as a control. Plasmid sequences for shEST can be found in 
APPENDIX A.  Lentiviral particles were generated using the second generation lentiviral system 
as described previously.               
 
  
Figure 8. EST Knockdown (KD) Functional Assay 
RT-PCR expression. (A) 293T cells were plated in 6 wells plates and grown to 80% confluency.  
Duplicate co-transfections were performed with 0.2ug pCMX-EST, 2ug pCMX-pl2 (empty 
vector), 2ug scrambled or knockdown plasmids when applicable. For EST KD, plasmid 4 was 
chosen for virus production. Sequences can be found in APPENDIX A.   
 
2.2.6 Adipocyte Culturing and Differentiation  
In all experiments except those in which exogenous estrogen (E2) was added, differentiation 
medium 1 (DM1) consisted of DMEM/F-12 medium, 10% standard FBS, 1% Pen-Strep, 33uM 
biotin, 100 nM insulin, 17 uM pantothenic acid, 0.5 mM methylisobutylxanthine,1 uM 
dexamethasone, and 1 uM rosiglitazone. Differentiation medium 2 (DM2) consisted of 
DMEM/F-12 medium, 10% FBS, 1% Pen-Strep, 1 uM dexamethasone, and 100 nM insulin. 
Confluent preadipocytes were cultured in DM1 for 3 days before being switched to DM2 for 2 
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weeks to reach terminal differentiation. Culture medium was changed every other day. For 
differentiation experiments in which E2 was exogenously added, the cells were cultured in 
phenol red-free DMEM/ F-12 medium and dextran-coated charcoal (DCC)-stripped FBS before 
the addition of E2 at a final concentration of 10 nM. 
2.2.7 Gene Expression Analysis  
Total RNA from preadipocytes/adipocytes was isolated using TRIZOL (Invitrogen) reagent. 
Total RNA from whole fat tissue or lipoaspirate was collected using the RNEASY Lipid Tissue 
Mid-Kits (Quiagen). The cDNA was synthesized from 1.0 ug of total RNA by Iscript from Bio-
Rad(Hercules, CA). Aliquots of cDNA were amplified on an ABI 7300 Real-Time PCR System 
from Applied Biosystems (Foster City, CA) using the SYBR green PCR master mix. mRNA 
expression was normalized against the expression of cyclophilin or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). A complete list of primers used can be found in APPENDIX A.  
Primers were validated using serial dilutions (1fg -10ng) of linearized expression vectors for the 
target gene or quantified cDNA from differentiated adipocytes to generate efficiency curves.  An 
example of an efficiency curve validating the EST primer can be found in APPENDIX A.  
2.2.8 Oil Red O Staining and Quantification 
Differentiated six-well culture dishes were washed twice with cold phosphate-buffered saline 
(PBS) and then prefixed for 1 h with 10% formaldehyde in PBS. After 1 hr, fresh 10% 
formaldehyde was added, and the cells were incubated overnight at room temperature. The next 
day, the cells were washed twice with PBS and then incubated in 60% isopropanol for 5 min, 
followed by drying at room temperature (RT). Cells were incubated with oil red O working 
solution for 10 minutes and then washed five times with deionized water. Images were acquired 
microscopically. For quantification of oil red O staining, cells were differentiated in triplicate in 
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24-well plates, stained with oil red O, and eluted with 100% isopropanol, and 100 uL of elute 
was loaded onto 96-well plates. Absorbance was measured at 500 nm using a PerkinElmer plate 
reader. 
2.2.9 Western Blot Analysis  
Cells were lysed with NP-40 lysis buffer containing protease inhibitors and then quantified for 
protein concentrations by a bicinchoninic acid (BCA) assay kit from Pierce (Rockford, IL). 
Protein samples were resolved by electrophoresis on 10% SDS-polyacryl-amide gels. For the 
detection of insulin receptor substrate 1 (IRS1) and its phosphorylation, cell lysates were 
immunoprecipitated with an IRS1 antibody before being subjected to Western blotting using an 
IRS1 antibody and phosphotyrosine antibody. After transfer of proteins to polyvinylidene 
difluoride (PVDF) membranes, the membranes were probed with antibodies against total 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) (catalog no. sc94; Santa Cruz), phospho-
ERK1/2 (catalog no.sc7383; Santa Cruz), total AKT (catalog no. 9272; Cell Signaling), phos-
pho-AKT (catalog no. 9215; Cell Signaling), phospho-CREB (catalog no.87G3; Cell Signaling), 
total CREB (catalog no. 48H2; Cell Signaling), human EST (catalog no. SAB1400267; Sigma), 
ERα (catalog no. sc7207;Santa Cruz), IRS1 (catalog no. 2382S; Cell Signaling), and 
phosphotyrosine (catalog no. ab10321; Abcam). Detection was achieved by using an ECL 
system from Amersham (Piscataway, NJ). Quantification was performed using the NIH ImageJ 
software. 
2.2.10 MTT Cell Proliferation Assay 
An MTT[3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay was 
performed using an assay kit from ATCC (Manassas, VA). Briefly, preadipocytes were grown in 
150cm dishes and treated with lentivirus expressing either EST or vector at an MOI of 3. Five 
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days later, cells were plated in triplicate at a density of 3 x103 cells per well in 96-well plates for 
1, 3, and 5 days. On the appropriate day, 10ul of MTT reagent was added to each well, and the 
cells were incubated for 3hrs at 37°C. Subsequently, 100 ul of detergent was added, and the cells 
were incubated overnight at RT before a colorimetric assessment was performed using a 
PerkinElmer plate reader at 570 nm. 
2.2.11 Transient Transfection Assay 
HepG2 cells or 293T cells were plated at a density of 2 x 106 cells per 48-well plate and 
incubated overnight. Transfection was performed using Trans-IT reagent from Mirus. Plasmids 
that were used in triplicate at an amount of 300 ng included pCMX-EST, pCMX-EST AAK, 
pCMX-ERα, pCMX-PPARγ, and pCMX. The triplicate plasmid amounts for pCMX-CBP, 
pCMX–β-Gal (where β-Gal is β-galactosidase), and tk-ERE-Luc (where ERE is estrogen 
response element Luc is luciferase) or tk-PPRE-Luc (where PPRE is peroxisome proliferator 
response element) were 50 ng, 200 ng, and 600ng, respectively. Cells were transfected and 
incubated for 24 h. Transfected cells were treated with the appropriate ligand for 24hrs using 
DMEM without phenol red and DCC FBS, followed by lysis and assays for luciferase and β-Gal 
activities. The luciferase activities were normalized to β-Gal activities. 
2.2.12 Statistical Analysis  
When applicable, results are presented as means ± standard deviations (SD) The Student t test 
was used to compare means of two groups and One-way ANOVA was used to compare the 
means of three or more groups. P values of less than 0.05 are considered to be significant. 
Repeated- measures ANOVA was used to compare means of two or more groups across multiple 
time points (MTT cell proliferation assay).  Linear regression analysis was performed using the 
Graph-Pad Prism software. 
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2.3 RESULTS 
2.3.1 EST Expression Increases during Adipogenesis  
We have previously reported that the expression of the mouse Est gene was high in 
preadipocytes, and expression decreased upon differentiation [3].  In an effort to determine 
whether the human EST affects the differentiation of human preadipocytes we found that in four 
independent cases of obese human preadipocytes isolated from the abdominal fat depot the 
mRNA expression of EST in preadipocytes was low, and differentiation led to a marked increase 
in mRNA expression EST expression (Fig 9A).  The protein expression showed that EST is 
expressed highest at the induction of differentiation, and this expression then begins to diminish 
by day 14 (Fig 9E).  The induction of EST coincided with the induction of adipocyte 
differentiation maker genes, such as PPARγ,  LPL, and aP2/ FABP4 (Fig 9B-D)[88]. These 
results demonstrate that the regulation pattern of EST in humans is the opposite of what we 
observed in murine models.  
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Figure 9. The Expression of EST was Induced During Adipogenesis. 
The expression of EST was induced during adipogenesis. (A to D) Preadipocytes were cultured and 
differentiated in standard medium for 14 days. Total RNA was extracted before and after differentiation, 
and the expression of EST (A), PPARγ (B), LPL (C), and aP2 (D) was measured by real-time PCR 
analysis. (E) Lysates from differentiated adipocytes were subjected to Western blot analysis to detect 
protein expression of EST over the course of the 14 day differentiation period  *, P < .05; ** , P <.01; ns, 
not statistically significant compared to vector. 
.  
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2.3.2   EST is induced by the Glucocorticoid Receptor  
The Glucocorticoid Receptor (GR) is an important nuclear receptor that regulates adipogenesis 
through its effect on the 5' adenosine monophosphate-activated protein kinase (AMPK) pathway. 
The activation of the AMPK pathway takes place when the body needs to utilize energy such as 
during exercise, and therefore leads to a catabolic metabolic state. During AMPK activation, 
anabolic and energy consuming pathways such as adipogenesis, gluconeogenesis, and protein 
synthesis are inhibited; while energy producing pathways such as beta oxidation, and glycolysis 
are stimulated [120].  
The Glucocorticoid Receptor (GR) has been shown to inhibit AMPK phosphorylation when 
activated by an agonist such as dexamethasone in rat and human adipocytes [121]. The inhibition 
of this pathway is essential for the accumulation of lipids in adipose tissue, however 
glucocorticoid excess such as in Cushing’s Syndrome or from exogenous glucocorticoid 
treatment can lead to an severe accumulation of lipids in visceral and adipose tissue as well as 
fatty liver [120, 121].  Typically metformin, an AMPK activator, is used to treat endogenous or 
exogenous glucocorticoid excess which demonstrates the severe impact this pathway exerts on 
lipid metabolism [122].  
Previously, we showed that the human SULT1E1 and mouse Sult1e1 promoters contained 
functional Glucocorticoid Response Elements (GRE) [123]. Additionally, we showed that 
pharmacologic activation of GR was sufficient to induce SULT1E1 expression and inhibit MCF-
7 cell growth in cell culture and in vivo due to estrogen deprivation [123].  
Based on the aforementioned data, we decided to analyze the DEX-GR- SULT1E1 pathway in 
human adipocytes.  One case of preadipocytes was expanded, separated into two groups and 
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plated for differentiation. One group was treated with standard differentiation media including 
DEX and the other lacked DEX. Differentiation proceeded for two weeks followed by gene 
expression analysis and lipid content measurement.  We found that in the group differentiated 
without DEX there was nearly no induction of EST or adipogenic gene expression PPARγ, LPL, 
aP2, or C/EBPα (Fig 10A).  We used oil red O staining to show the paucity of lipid droplets 
formed in the samples differentiated without DEX (Fig 10B).  Additionally, the mRNA 
expression of the GR remained high throughout the experiment and did not change under either 
condition (Fig 11). These results strongly suggest that the DEX-GR-SULT1E1 pathway is 
conserved in human adipocytes and is necessary for efficient induction of EST and adipogenesis.  
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Figure 10.  DEX depravation during differentiation fails to induce SULT1E1 expression 
and adipogenesis. Preadipocytes were cultured and differentiated in standard medium or medium 
lacking DEX for 14 days. Total RNA was extracted before and after differentiation, and the expression of 
(A) EST and adipogenic genes was measured by real-time PCR analysis. (B) Samples were fixed, dried 
and stained with oil red O. Images were acquired microscopically. *, P < .05; ** , P <.01; ns, not 
statistically significant compared to vector. 
 
     
Figure 11.  DEX depravation during differentiation does not alter GR mRNA expression. 
The expression of the GR remained very high (relative to GAPDH) throughout the 
differentiation process and was unchanged by culturing conditions. CT values for pre, no DEX, 
and DEX were approximately 21, 20.5, 20.8 respectively; compared to the CT values of the 
housekeeping gene, GAPDH, approximately 15 for all groups. ns, not statistically significant.  
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2.3.3 Over-expression of EST Increases Adipogenic and Lipogenic Gene Expression but 
does not change Lipolytic Gene Expression 
2.3.3.1 Adipogenic mRNA expression in Obese and Lean Patients 
To determine the functional relevance of EST induction during adipogenesis, we overexpressed 
EST in preadipocytes before subjecting them to differentiation. Four cases of preadipocytes from 
obese patients were transduced with lentivirus expressing EST or the vector control, and then 
induced to terminal differentiation for 2 weeks. Lentivirus transduction was confirmed via GFP 
fluorescence microscopy (Fig 12C) and the overexpression of EST was confirmed by real-time 
PCR (Fig 12A.) and Western blotting (Fig 12B, D.).  Overexpression of EST promoted 
adipogenesis (Fig 13) as confirmed by gene expression analysis. Adipogenic gene expression 
changes included the induction of PPARγ, LPL, aP2, and C/EBPα( 13A-D). As stated in the 
introduction, the C/EBPs are vital for adipogenesis. C/EBPα has been shown to facilitate the 
activation of PPARγ target genes, whereas C/EBPβ and C/EBPδ are important for the 
transactivation of PPARγ gene expression. We also show that adipogenesis in cells transduced 
with EST-expressing virus was associated with the induction of C/EBPα  (Fig 13D), but the 
expression of C/EBPβ and C/EBPδ was unchanged (Fig 13E-F).  
We also transduced three cases of lean patients with lentivirus expressing EST and analyzed 
them to assess if pro-adipogenic metabolic changes were conserved in these samples also.  
Indeed, over-expression of EST enhanced adipogenesis in these samples as well, (Fig 14A-D) 
confirmed by genetic analysis of adipogenic genes that showed the induction of PPARγ, LPL, 
aP2, and C/EBPα, but no change was observed in C/EBPβ and δ (Fig 14E/F). Taken together, 
these results indicate that EST is a potent enhancer of adipogenic mRNA expression in our cell 
culture model. 
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Figure 12.  Lentiviral Transduction and Overexpression of EST.  In preadipocytes EST 
expression is low, we successfully transduced and overexpressed EST using lentivirus. Total 
RNA was extracted 3 days after transduction and the expression of EST was measured by (A) 
Real time PCR (B) Western Blot (C) The lentiviral construct contains a GFP tag which was also 
used to measure transduction efficiency in vector and EST treated cells (D) Lysates from 
differentiated vector and EST-virus treated cells were subjected to Western blot analysis to 
detect protein expression of EST over the 14 day differentiation period.  Pre, preadipocyte; V, 
vector; E, EST. 
            Vector                                             EST C 
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 Figure 13.  Adipogenic Gene Expression in Obese Patients. Overexpression of EST promoted 
Adipogenesis in Obese Patients. (A-F) Preadipocytes were transduced with vector or EST-
expressing lentivirus, then were cultured and differentiated in standard medium for 14 days. Total 
RNA was extracted before and after differentiation, and the expression of indicated adipogenic 
genes was measured by real-time PCR. *, P < .05; ** , P <.01; ns, not statistically significant 
compared to vector. 
 
C/EBPβ
6 7 8 9
0.0
0.5
1.0
1.5
2.0
2.5 ns ns
ns
ns
Patient
Re
lat
ive
 E
xp
re
ss
io
n
C/EBPδ
6 7 8 9
0.0
0.5
1.0
1.5
2.0
ns ns ns
ns
Patient
Re
lat
ive
 E
xp
re
ss
io
n
A B 
C D 
E F 
38 
 
  
Figure 14.  Lean Patients Adipogenic Gene Expression. 
Overexpression of EST promoted Adipogenesis in Lean Patients. (A-F) Preadipocytes were 
transduced with vector or EST-expressing lentivirus, then were cultured and differentiated in 
standard medium for 14 days. Total RNA was extracted before and after differentiation, and the 
expression of indicated adipogenic genes was measured by real-time PCR. *, P < .05; ** , P 
<.01; ns, not statistically significant compared to vector. 
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2.3.3.2 Lipogenic and Lipolytic mRNA expression in Obese and Lean Patients 
We also analyzed the expression of lipogenic genes, because the adipogenesis and lipogenesis 
pathways are not mutually exclusive and in fact converge at many points. In the introduction, we 
discussed the genes which are critical for the induction of lipogenesis, specifically sterol 
regulatory element binding protein 1c (SREBP1c), acetyl-coenzyme A (CoA) carboxylase1 
(ACC1), fatty acid synthase (FAS), and stearoyl CoA desaturase 1 (SCD1). The activation of 
these genes is directly and indirectly effected by adipogenic transcription factors and insulin 
signaling (section 2.1 background: molecular mechanism controlling adipogenesis and 
lipogenesis).  
 
The over-expression of EST in the overweight/obese cohort enhanced the expression of several 
lipogenic genes, including SREBP1c and its target genes ACC, FASN and SCD1 (Fig 15). In 
contrast, the expression of the lipolytic genes, adipose triglyceride lipase (ATGL) and Hormone 
sensitive lipase (HSL) were not affected by EST overexpression (Fig 17). The lipogenic and 
lipolytic results were also recapitulated in 3 independent cases from lean patients (Fig 16 and 
18).  Taken together, these results indicate that EST has the ability to potentiate the mRNA 
expression of adipogenic and lipogenic genes, while the expression of genes involved in lipolysis 
is unchanged in obese and lean patients.   
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 Figure 15. Obese Patients Lipogenic Gene Expression 
Overexpression of EST promoted Lipogenesis in Obese Patients. (A-D) Preadipocytes were 
transduced with vector or EST-expressing lentivirus, then were cultured and differentiated in 
standard medium for 14 days. Total RNA was extracted before and after differentiation, and the 
expression of indicated lipogenic genes was measured by real-time PCR. *, P < .05; ** , P <.01; 
ns, not statistically significant compared to vector. 
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 Figure 16. Lean Patients Lipogenic Gene Expression 
Overexpression of EST promoted Lipogenesis in Lean Patients. (A-D) Preadipocytes were 
transduced with vector or EST-expressing lentivirus, then were cultured and differentiated in 
standard medium for 14 days. Total RNA was extracted before and after differentiation, and the 
expression of indicated lipogenic genes was measured by real-time PCR. *, P < .05; **, P <.01; 
ns, not statistically significant compared to vector. 
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 Figure 17. Obese Patients Lipolytic Gene Expression.  
Overexpression of EST did not change lipolysis in Obese Patients. (A-B) Preadipocytes were 
transduced with vector or EST-expressing lentivirus, then were cultured and differentiated in 
standard medium for 14 days .Total RNA was extracted before and after differentiation, and the 
expression of indicated lipolytic genes was measured by real-time PCR. *, P < .05; ** , P <.01; 
ns, not statistically significant compared to vector. 
 
 
 
Figure 18. Lean Patients Lipolytic Genes 
Overexpression of EST did not change lipolysis in Lean Patients. (A-B) Preadipocytes were 
transduced with vector or EST-expressing lentivirus, then were cultured and differentiated in 
standard medium for 14 days. Total RNA was extracted before and after differentiation, and the 
expression of indicated lipolytic genes was measured by real-time PCR. *, P < .05; ** , P <.01; 
ns, not statistically significant compared to vector. 
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2.3.4 Over-expression of EST Increases Lipid Droplet Accumulation in Obese and Lean 
Patients  
The final outcome of adipogenesis and lipogenesis is the synthesis and storage of fatty acids and 
triglycerides. We quantitatively and qualitatively measured the accumulation of fatty acids in 
four obese patients using oil red O dye. We found that cells overexpressing EST accumulated 
significantly more lipid content than cells transduced with vector virus (Fig 19). Additionally, 
when we analyzed the lipid content in three lean patients, we found the same EST promoting 
effect on lipid accumulation in these cells as well (Fig 20). Taken together, these results indicate 
that EST has the ability to potentiate adipogenesis and lipogenesis at the molecular genomic 
level, leading to a significant induction in the number of adipocytes, lipid droplet formation and 
storage.  
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 Figure 19. EST Increases Lipid Droplet Formation in Overweight/Obese Patients 
Preadipocytes from obese patients were transduced with vector or EST-expressing lentivirus, 
then were cultured and differentiated in standard medium for 14 days. (A-D) Cells were then stained 
with oil red o dye, and examined microscopically as well as quantitatively.                                  
*, P < .05; ** , P <.01; OD500, optical density at 500nm.  
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Figure 20. EST Increase Lipid Droplet Formation in Lean Patients  
Preadipocytes from lean patients were transduced with vector or EST-expressing lentivirus, then 
were cultured and differentiated in standard medium for 14 days. (A-D) Cells were then stained with 
oil red o dye, and examined microscopically as well as quantitatively. *, P < .05; ** , P <.01; 
OD500, optical density at 500nm.  
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2.3.5 Analysis of EST Over-Expression and Insulin Sensitivity 
The increase in adipogenesis and lipogenesis, led us to investigate the underlying mechanisms 
promoting this change. The insulin signaling pathway was analyzed to assess if EST promoted 
insulin signaling or sensitivity. The Insulin Receptor substrate 1 (IRS-1), the serine/threonine 
protein kinase B (PKB/AKT) and the cAMP responsive element binding protein (CREB) 
signaling were examined, because these molecules play an integral role in the insulin signaling 
pathway.  In general the signaling pathway is activated when insulin binds to the insulin 
receptor, a transmembrane tyrosine kinase receptor, resulting in insulin receptor (IR) 
autophosphorylation and activation [124]. The activated IR phosphorylates several 
adaptor/scaffold molecules including the Insulin Receptor Substrate (IRS) family of proteins.  
The phosphorylation of IRS-1 is a rapid response after insulin treatment  and leads to the 
recruitment of effectors such as phosphoinositide 3-kinase (PI3K), which phosphorylates AKT 
[124]. Finally, activated AKT can phosphorylate CREB which acts as a transcription factor that 
can bind to its DNA motif and promote cell survival and differentiation [125, 126].  
2.3.5.1 Over-expression of EST Increases AKT and CREB signaling in Obese and Lean 
Patients  
It was found that EST promoted phosphorylation of AKT and CREB in terminally differentiated 
cells from obese patients (Fig 21). Additionally increased AKT signaling in EST transduced 
cells from lean patients was identified (Fig 22).  
To analyze if the increased AKT and CREB signaling is a primary effect exerted by EST 
expression, we transduced preadipocytes with EST and Vector viruses and treated them with 
insulin for 10 minutes.  We found that the phosphorylation of the insulin receptor substrate 1 
(IRS1) was similarly increased in vector transduced and EST transduced cells (Fig 23). These 
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results were surprising because the activation of the inulin signaling pathway typically occurs 
instantaneously after insulin treatment. This suggests that downstream changes in insulin 
signaling (AKT and CREB) are secondary effects that may be primarily promoted by changes in 
adipogenic gene expression. Additionally, as mentioned in the introduction (C/EBP family), 
C/EBPα signaling has been reported to be critical in the regulation of insulin signaling and 
sensitivity [21, 74]. It is feasible that the increased C/EBPα expression we reported may induce 
AKT and subsequent CREB signaling, albeit still secondary to the primary genomic changes that 
are taking place.  
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Figure 21. Obese/Overweight Patients AKT and CREB Signaling  
Lysates from differentiated vector and EST-virus treated cells from obese patients were 
subjected to Western blot analysis to detect protein expression of (A-B) total AKT, phospho-
AKT (p-AKT) and quantification, (C-D) total CREB, and phospho-CREB (p-CREB) and 
quantification. The signals were quantified by using NIH ImageJ software (n=2). *, P < .05; **, 
P <.01. 
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Figure 22. EST Increases AKT signaling in Lean Patients  
Lysates from differentiated cells were subjected to Western blot analysis to detect protein 
expression of (A-B) total AKT, phospho-AKT (p-AKT), The signals were quantified by using 
NIH ImageJ software (n=2). *, P < .05; ** , P <.01. 
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2.3.5.2  Over-expression of EST does not Enhance IRS-1 Signaling  
 
 
 
 
 
 
 
Figure 23.  EST does not Directly Increase Insulin Signaling  
Preadipocytes from obese patients were transduced with EST or vector viruses and grown to 
confluency. They were then treated with insulin (100 nM) for 10 min before being evaluated for 
the protein expression of total IRS1 and phospho-IRS1 by immunoprecipitation and Western 
blotting. The signals were quantified by using NIH ImageJ software (n=2) 
 
2.3.6 Analysis of EST Overexpression and ERK Signaling 
2.3.6.1 Over-expression of EST Increases ERK Signaling  
The extracellular signal related kinases (ERK1/2) is an essential component of the MAPK 
signaling pathway that is linked to cell proliferation [127]. Recently it was reported the ERK1/2 
signaling may also be important for the recruitment and commitment of undifferentiated 
preadipocytes to begin the differentiation process [128]. 
We observed that ERK1/2 signaling was increased in terminally differentiated EST cells 
compared to vector cells (Fig 24A).  Consistent with the increased ERK1/2 phosphorylation, the 
proliferation of EST cells was indeed increased compared to the vector cells in the early phase of 
growth, although the difference in proliferation became non-significant after three days of 
culturing when the cells became more confluent(Fig  24B). To test the significance of ERK 
A 
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signaling on adipogenesis we grew EST or vector virus transduced cells to confluency and 
cultured them in differentiation media containing the ERK phosphorylation inhibitor PD98059.  
Interestingly, the addition of the ERK1/2 inhibitor PD98059 had little effect on the mRNA  
expression or lipid droplet formation of either the vector or EST cells (Fig 26-27). These results 
indicate that the increased ERK 1 /2 signaling is most likely a secondary effect since inhibition 
of said signaling had no effect on adipogenesis in the vector or EST-virus transduced cells.  
 
 
Figure 24. ERK Protein Expression and MTT Cell Proliferation Assay 
(A)Lysates from differentiated cells were subjected to Western blot analysis to detect the protein 
expression of total ERK1/2and phospho-ERK1/2 (p-ERK).(B) Preadipocytes were transduced 
with vector- or EST-expressing lentivirus and grown in triplicate for each time point and 
examined by an MTT proliferation assay(n=2). *, P < .05; ** , P <.01. 
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2.3.6.2  Pharmacologic Inhibition of ERK Signaling does not ablate EST effect  
 
 
 
Figure 25.   Pharmacological Inhibition of ERK in obese adipocytes.  
Preadipocytes were grown to confluency then cultured in differentiation media containing the 
ERK1/2 inhibitor PD98059 for 14 days. Lysates were collected and subjected to Western blot 
analysis.  
 
Figure 26. Inhibition of ERK does not affect Adipogenic Gene Expression. 
Preadipocytes from obese patients were grown to confluency then cultured in differentiation 
media containing the ERK1/2 inhibitor PD98059 for 14 days. Total RNA was extracted before 
and after differentiation, and the expression of indicated adipogenic genes was measured by real-
time PCR (n=1). ns, not significant compared to vector.  
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Figure 27. Inhibition of ERK does not affect Oil Red O staining  
Preadipocytes from obese patients were transduced with vector or EST-expressing lentivirus, 
then were cultured in differentiation medium containing the ERK1/2 inhibitor PD98059for 14 days. (A-
B) Cells were then stained with oil red o dye, and examined microscopically as well as 
quantitatively in triplicate groups (n=1).  OD500, optical density at 500nm; ns, not statistically 
significant compared to vector.  
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2.3.7   Site Directed Mutagenesis of  3'-Phosphoadenosine 5'-phosphosulfate (PAPS) 
binding domain 
EST catalyzes the transfer of a sulfonate group from the universal sulfonate donor 3-
phosphoadenosine 5- phosphosulfate (PAPS) to the estrogens. To assess whether the enzymatic 
activity of EST is necessary for the pro-adipogenic effect, we generated a lentivirus expressing a 
mutant human EST lacking enzymatic activity [2]. We along with others have reported that by 
mutating a conserved domain in the P-loop region of the PAPS-binding domain from GxxGxxK 
(GGK) to AxxAxxK (AAK), the enzymatic activity of EST was completely abolished[3, 118]. 
The lack of enzymatic activity of the EST AAK mutant was validated in a transfection and 
reporter gene assay in which the estrogen-deactivating activity of wild-type EST was abolished 
in cells transfected with a virus expressing the EST AAK mutant (Materials and Methods 2.2.4). 
The expression of EST AAK in transduced preadipocytes was confirmed by fluorescence 
microscopy analysis of GFP and Western blotting (Fig 29). The lack of adipogenic activity of 
EST AAK was also supported by the lack of induction of adipogenic gene expression (Fig 30) 
and phosphorylation of AKT and ERK (Fig 30). These results indicate that pro-adipogenic of 
EST is dependent on its enzymatic activity, and does include passive interaction with other 
proteins or transcription factors.  
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 Figure 28.  Multiple Sequence Alignment of PAPS binding domain  
(Upper panel) Multiple sequence alignment of the he P-loop region of the PAPS binding domain 
in rat, mouse, and human showing conservation across multiple species. (Lower panel) EST 
dimeric subunit structure with PAPS binding domain highlighted in yellow.   
 
 
 
Figure 29.  Transduction of AAK EST, EST, and VECTOR Lentivirus into 
Preadipocytes(A) Preadipocytes were transduced with vector, EST, and EST-AAK viruses and 
analyzed for GFP with fluorescence microscopy and (B) Lysates were collected and subjected to 
Western blot analysis.  
 
    Vector                        EST          EST-AAK 
    Vector          EST          EST-AAK 
          EST 
      
β  Actin 
A 
B 
RAT  
HUMAN 
MOUSE 
A 
57 
 
  
 
 
Figure 30.  Adipogenic Gene Expression and Western Blot Analysis  
Preadipocytes were transduced with vector- or AAK-expressing lentivirus and then induced to 
differentiate for 14 days before being evaluated for gene expression analysis by (A)  real-time 
PCR  and (B) Western blot analysis to detect total AKT, phospho-AKT, total ERK1/2, and 
phospho-ERK1/2 (n=1). ns, not statistically significant compared to vector.   
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2.4 RESULTS (B) KNOCKDOWN OF EST AND PHARMACOLOGIC INHIBITION IN 
OBESE AND LEAN PATIENTS INHIBITS ADIPOGENESIS AND LIPOGENESIS  
2.4.1 Pharmacologic Inhibition of EST inhibits Adipogenesis  
In the previous section we demonstrated that over-expression of EST promoted adipogenesis and 
lipogenesis through increased adipogenic/lipogenic gene expression, lipid droplet formation, and 
increased insulin signaling. We then wanted to determine if the opposite effect would be seen if 
we inhibited EST.  
It has been reported that Triclosan, an antimicrobial agent, is an inhibitor of EST [129, 130]. 
Specifically, Triclosan can bind to the E2 binding pocket in EST causing the formation of 
Triclosan-sulfate conjugates instead of E2 sulfate conjugates [130]. We tested the specificity of 
Triclosan inhibition of EST in a luciferase reporter assay where we compared the inhibition of 
EST to the inhibition of hydroxysteroid sulfotransferase (SULT2A1), a sulfotransferase known 
to sulfate and deactivate androgens. We transfected tk-ERE-LUC and pCMX-ERα into 293T 
cells and treated them with 10nM E2. We found that the EST mediated sulfation and repression 
of E2-ERa activation was abolished when the cells were co-cultured with 10uM Triclosan (Fig 
31A). We performed the same assay with tk-AR-LUC and pCMX-AR and found that Triclosan 
did not inhibit SULT2A1 sulfation and repression on the Androgen Receptor after ligand 
treatment (Fig 31B).  
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Figure 31.  Triclosan can Specifically Inhibit EST   
Luciferase Reporter Assay showing Triclosan specificity in 293T cells. (A) tk-ERE-LUC 
reporter and pCMX-ERα was transfected into 4 triplicate groups. The cells were treated with E2 
(10nM), Triclosan (10uM) and transfected with pCMX-EST when applicable. (B) tk-AR-LUC 
reporter and pCMX-AR was transfected into 4 triplicate groups. The cells were treated with 
Testosterone (50nM), Triclosan (10uM) and transfected with pCMX- SULT2A1 when 
applicable. ERE, Estrogen response element; AR, Androgen response element;*, P < .05; ** , P 
<.01; ns, not statistically significant.  
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Next we decided to analyze the effects of Triclosan in our differentiation cell culture model. We 
cultured one patient sample in differentiation media containing 10uM Triclosan for 14 days and 
found inhibition on the mRNA expression of PPARγ and its target genes LPL and aP2 (Fig 32B). 
Additionally, we found reduced lipid droplet formation compared to the vehicle treated group 
(Fig 32A). These results indicate that Triclosan is a specific inhibitor of EST and that 
pharmacologic inhibition of EST has significant consequences on the adipogenesis in our model.   
 
 
Figure 32. Triclosan Inhibits Differentiation  
Preadipocytes were induced to differentiate for 2 weeks in the presence of 10 uM Triclosan or 
vehicle (Veh) before being evaluated for oil red O staining (A) and the expression of adipogenic 
genes and EST (B). (n=2) *, P < .05; ** , P <.01; ns, not statistically significant 
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2.4.2  Knockdown of EST Inhibits Adipogenic, Lipogenic, and Lipolytic Gene Expression 
in Obese and Lean Patients 
Based on our results from the pharmacologic inhibition of EST using Triclosan, we decided to 
determine if genetic knockdown could recapitulate the same effects. Additionally, we were 
concerned that some of the effects that we saw in the Triclosan assay could be based on toxicity. 
We created two knockdown viruses that express the shRNA against EST, shEST and a scrambled 
control virus, shSCR (See virus production in Methods section). Two obese patient samples and 
3 lean patients were used to test the adipogenic and lipogenic effect of EST Knockdown (KD).  
We treated the cells with either shEST or shSCR virus, and proceeded to terminally differentiate 
the cells for two weeks. Cells were then analyzed for gene expression, lipid content, and protein 
expression. The gene expression profile in our obese patients confirmed that we had knocked 
down EST (Fig 33), and additionally that KD of EST caused significant reduction in adipogenic 
and lipogenic mRNA expression. PPARγ and its target genes LPL and a P2 were both 
significantly inhibited compared to shSCR (Fig 33). C/EBPα was only inhibited in one obese 
patient sample, but similar to the over-expression model there was no change in 
C/EBPβ expression (Fig 33). There was also an inhibition of the lipogenic and lipolytic genetic 
profile in the obese patients; specifically an attenuation of SREBP1c, FASN, SCD1, and ACC 
(Fig 34) expression as well as ATGL, and HSL (Fig 35) respectively. Further, the results from 
the adipogenic, lipogenic and lipolytic RT-PCR analysis in obese patients, were recapitulated in 
the 3 lean patients tested (Fig 36-38).  Taken together, these finding indicate that EST KD has a 
significant impact on adipogenesis and lipogenesis at the genomic level. The ability to reduce the 
mRNA expression of the aforementioned adipogenic and lipogenic enzymes is an important and 
novel function of EST in adipocytes.  
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Figure 33. Knock down of EST Inhibits Adipogenic Gene Expression in Obese Patients 
Knockdown of EST attenuated adipogenesis in Obese Patients. (A) Preadipocytes were 
transduced with shSCR or shEST-expressing lentivirus, then were cultured and differentiated in 
standard medium for 14 days. Total RNA was extracted before and after differentiation, and the 
expression of indicated adipogenic genes was measured by real-time PCR. *, P < .05; **, P 
<.01; ns, not statistically significant compared to vector. 
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Figure 34.  Knockdown of EST Inhibits Lipogenic Gene Expression in Obese Patients 
Knockdown of EST attenuated lipogenesis in Obese Patients. (A) Preadipocytes were 
transduced with shSCR or shEST-expressing lentivirus, then were cultured and differentiated in 
standard medium for 14 days. Total RNA was extracted before and after differentiation, and the 
expression of indicated lipogenic genes was measured by real-time PCR. *, P < .05; **, P <.01; 
ns, not statistically significant compared to vector. 
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 Figure 35.  Knockdown of EST Inhibits Lipolytic Gene Expression in Obese Patients  
Knockdown of EST attenuated lipolysis in Obese Patients. (A) Preadipocytes were transduced 
with shSCR or shEST-expressing lentivirus, then were cultured and differentiated in standard 
medium for 14 days. Total RNA was extracted before and after differentiation, and the expression 
of indicated lipolytic genes was measured by real-time PCR. *, P < .05; **, P <.01. 
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 Figure 36. EST Knockdown Inhibits Adipogenic Gene Expression in Lean Patients  
Knockdown of EST attenuated adipogenesis in Lean Patients. (A) Preadipocytes were 
transduced with shSCR or shEST-expressing lentivirus, then were cultured and differentiated in 
standard medium for 14 days. Total RNA was extracted before and after differentiation, and the 
expression of indicated adipogenic genes was measured by real-time PCR. *, P < .05; **, P 
<.01; ns, not statistically significant compared to vector. 
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 Figure 37.  Knockdown of EST Inhibits Lipogenic Gene Expression in Lean Patients 
Knockdown of EST attenuated lipogenesis in Lean Patients. (A) Preadipocytes were transduced 
with shSCR or shEST-expressing lentivirus, then were cultured and differentiated in standard 
medium for 14 days. Total RNA was extracted before and after differentiation, and the expression 
of indicated lipogenic genes was measured by real-time PCR. *, P < .05; **, P <.01. 
 
Figure 38. Knockdown of EST Inhibits Lipolytic Gene Expression in Lean Patients 
Knockdown of EST attenuated lipolysis in Lean Patients. (A) Preadipocytes were transduced 
with shSCR or shEST-expressing lentivirus, then were cultured and differentiated in standard 
medium for 14 days. Total RNA was extracted before and after differentiation, and the expression 
of indicated lipolytic genes was measured by real-time PCR. *, P < .05; **, P <.01 
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2.4.3 EST Knockdown Inhibits Lipid Droplet Accumulation in Obese and Lean Patients 
As stated in the previous section detailing the EST over-expression experiments, the functional 
endpoint of adipogenesis and lipogenesis is the synthesis and storage of fatty acids and 
triglycerides. We quantitatively and qualitatively measured the accumulation of fatty acids in 
two obese patients using oil red O dye and NIH ImageJ software. The knockdown of EST had a 
marked inhibitory impact on the synthesis and storage and fatty acids compared to the shSCR 
control treated cells (Fig 39).  Microscopically, the shEST cells remained morphologically 
similar to fibroblasts, with small lipid droplets forming in a scattered pattern; compared to the 
shSCR cells which had many lipid clusters throughout the dish (Fig 39). Additionally, we 
recapitulated these results in 3 lean patients as well (Fig 40).  These results suggest that the loss 
of EST mRNA expression in obese and lean patients leads to significant attenuation of lipid 
storage and synthesis.  
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 Figure 39.  Knockdown of EST Inhibits Lipid Droplet Formation in Obese Patients  
Preadipocytes from obese patients were transduced with shSCR or shEST-expressing lentivirus, 
then were cultured and differentiated in standard medium for 14 days. (A-B) Cells were then stained 
with oil red o dye, and examined microscopically as well as quantitatively.                                  
*, P < .05; ** , P <.01; OD500, optical density at 500nm.  
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 Figure 40. Knockdown of EST Inhibits Lipid Droplet Formation in Lean Patients  
Preadipocytes from Lean patients were transduced with shSCR or shEST-expressing lentivirus, 
then were cultured and differentiated in standard medium for 14 days. (A-B) Cells were then stained 
with oil red o dye, and examined microscopically as well as quantitatively.                                  
*, P < .05; ** , P <.01; OD500, optical density at 500nm.  
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2.4.4 EST Knockdown Inhibits AKT and CREB signaling 
Similar to the over-expression experiments, we decided to analyze the insulin signaling pathway 
to assess if EST KD attenuated insulin signaling or sensitivity. Again we analyzed AKT and 
CREB activation, two integral signaling molecules in the insulin secondary messenger pathway. 
Here we found that EST KD did inhibit AKT and CREB signaling compared to shSCR in obese 
patients (Fig 41-42). Due to limitations in available cells, we were unable to analyze this 
pathway in lean patients, however based on the gene expression and oil red O results, we are 
confident that the attenuation of AKT and CREB is also reflected in lean patients. 
 
Figure 41. Knockdown of EST Inhibits AKT Signaling in Obese Patients 
Lysates from differentiated shSCR and shEST-virus treated cells from obese patients were 
subjected to Western blot analysis to detect protein expression of (A-B) total AKT, phospho-
AKT (p-AKT), The signals were quantified by using NIH ImageJ  software (n=2). *, P < .05; ** 
, P <.01. 
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Figure 42.  Knockdown of EST Inhibits CREB signaling in Obese patients  
Lysates from differentiated shSCR and shEST virus treated cells from obese patients were 
subjected to Western blot analysis to detect protein expression of (A-B) total CREB, and 
phospho-CREB (p-CREB). The signals were quantified by using NIH ImageJ software. *, P < 
.05; ** , P <.01. 
 
 
 
 
 
 
 
 
 
 
72 
 
2.5 DISCUSSION 
These studies were driven by observations that EST had a repressive role on adipogenesis in 
mice, however we have uncovered the opposite effect in human ASCs; here we show a novel 
functional role for EST in human adipogenesis. To summarize the major findings of this section: 
(1) In preadipocytes the mRNA expression of EST is low and differentiation causes 
increased expression of EST mRNA. Moreover we observed the protein expression of 
EST is highest at the beginning of differentiation and the expression begins to diminish 
during the 14 day culture period (Fig 9). 
(2) Dexamethasone treatment during differentiation induces EST mRNA expression, and 
differentiation without DEX treatment causes no induction of EST, moreover, previously 
we published data which shows that there is a glucocorticoid response element in the 
promoter region of EST [123](Fig 10).  
(3) Over-expression of EST using lentivirus leads to significant genomic changes in obese 
and lean patients which include an enhanced induction of PPARγ and PPARγ target 
genes (LPL and aP2) and C/EBP compared to vector (Fig 13-14) . Additionally, we 
observed a promotion of lipogenic signaling mRNA that included SREBP1c, ACC, 
FASN, and SCD1(Fig 15-16). We did not see a difference in lipolytic mRNA signaling 
between the vector and EST groups (Fig 17-18).  
(4) Over-expression of EST in obese and lean patients caused an increase in lipid droplet 
formation compared to vector treated cells as noted using Oil Red-O staining and 
quantification (Fig 19-20). 
(5) Over-expression of EST markedly increased the terminal protein expression of AKT, 
CREB, and ERK 1/2 in obese patients (Fig 21, 24) and enhanced AKT signaling in lean 
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patients (Fig 22). However we did not see a primary difference in rapid (10 minute 
treatment) IRS1 signaling between the vector and EST treated cells (Fig 23). Moreover, 
the pharmacologic inhibition of ERK1/ 2 signaling during adipogenesis had no effect on 
enhanced adipogenic mRNA expression or lipid droplet formation caused by EST over-
expression (Fig 25-27).  
(6) Genetic knock-down and pharmacologic inhibition of EST in obese and lean patients 
caused the opposite effects as those in the over-expression model. Specifically, we 
observed a marked decrease in adipogenic, lipogenic, and lipolytic mRNA signaling; 
lipid droplet formation, and AKT/ CREB signaling (Fig 33-42).  
(7) The changes observed from over-expressing or knocking down EST are dependent on the 
enzymatic activity of EST as shown in section 2.3.7, where we created an enzymatically 
dead mutant that had no effect on adipogenic gene signaling, or AKT/CREB activity.  
Our results demonstrate that EST acts as a positive regulator of adipogenesis in human 
abdominal preadipocytes and adipocytes taken from both lean and obese female patients. We 
observed that at the mRNA level, EST expression is low in preadipocytes and differentiation 
leads to a marked induction of this expression (Fig 9A-F). Moreover, our time course of EST 
protein expression indicates that EST is expressed highest at the beginning of differentiation and 
this expression begins to diminish over the course of the 14 day differentiation period (Fig 9E). 
Additionally, we demonstrated that without Dexamethasone treatment during differentiation, 
EST is not induced at the mRNA level along with most other adipogenic enzymes and markers. 
These results strongly suggest that the DEX-GR-SULT1E1 pathway elucidated in MCF-7 cells 
and in vivo mouse models [123] is conserved in human adipocytes and is necessary for efficient 
induction of EST and adipogenesis. These results also show that along with the array of other 
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adipogenic transcription factors and enzymes, EST displays temporal and spatial expression 
during adipogenesis. Moreover, since EST is highly expressed at the beginning of differentiation, 
this suggests that EST is important for the commitment of preadipocytes to mature into 
functional adipocytes.  
The preadipocytes taken from our patient population of lean and obese females undergo both 
genomic and functional changes that promote or attenuate adipogenesis and lipogenesis as a 
result of EST over-expression or knock down, respectively.  The promotion of adipogenesis and 
lipogenesis at the genomic and lipid level was coupled with increased AKT, CREB, and ERK 
protein signaling; conversely we observed the opposite when EST was knocked- down. The fact 
that EST is highly expressed at the beginning of differentiation and diminishes over the course of 
the 14 day differentiation period indicates that this may be a critical regulatory mechanism to 
mediate a healthy level of adipocyte formation and lipid synthesis.  When we over-expressed 
EST we ectopically caused sustained expression of EST throughout the entire course of 
differentiation, which facilitated increased adipogenesis (Fig 10). Likewise, when we knocked 
down the mRNA expression of EST, the lack of induction at beginning of differentiation 
attenuated the expression of adipogenic and lipogenic genes. Taken together our data suggests 
that EST has the ability to mediate the response of the preadipocyte to stimulation by adipogenic 
cues. The mechanisms through which EST can mediate the adipogenic response are unknown 
and became the next focus of our experiments.  
We observed after terminal differentiation that the overexpression of EST increased AKT/CREB 
signaling, while the opposite was seen after knockdown of EST. Initially we analyzed whether 
EST is primarily increasing insulin signaling through AKT/CREB, subsequently leading to 
increased adipogenic and lipogenic mRNA signaling and lipid accumulation. To do this we used 
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Co–Immunoprecipitation assays (Co-IP) to detect initial changes in IRS-1 phosphorylation 
between EST and vector transduced cells (Fig  23). Our assay showed that after 10 minutes of 
insulin treatment there was no difference in IRS-1 phosphorylation between vector and EST-
virus transduced cells (Fig 23).  
Additionally, we observed that EST-virus transduced cells had increased ERK 1/2 protein 
signaling (Fig 24). Therefore we analyzed if modulating ERK signaling was a primary signaling 
effect facilitated by EST-overexpression that lead to increased adipogenic/lipogenic mRNA 
signaling. To test this we cultured vector and EST cells in standard differentiation media 
containing an ERK inhibitor for two weeks (Fig 25-27). Interestingly, we found that this did not 
attenuate the adipogenesis promoting effects of EST.  Collectively, these data suggest that the 
promotion of AKT, CREB, and ERK 1/2 signaling is not the primary driving force behind EST 
stimulated adipogenesis. These are most likely secondary effects that become apparent in 
terminally differentiated cells which are transduced with EST virus.   
The primary role of EST is to sulfate and deactivate estrogen, and based on the vast array of data 
detailing the effects of estrogen in abdominal subcutaneous adipose tissue (covered in  section 
1.2.2  ERα/β), the observations shown here strongly suggest that EST is promoting adipogenesis 
by diminishing the repressive effects imposed by estrogen signaling. Adipogenesis is activated at 
the genomic level primarily through PPARγ activation.  Mechanistically, it is feasible that by 
inhibiting estrogen signaling coactivator recruitment is shifted toward PPARγ. Once PPARγ is 
robustly activated it subsequently promotes a commensurate adipogenic and lipogenic response.  
Increased PPARγ signaling can directly increase its own target genes (LPL and aP2) as well as 
C/EBPα (Fig 4). Additionally, as reported in section 1.2.3, C/EBPα activation is paramount for 
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proper insulin signaling [21, 74]. The observed increase in C/EBPα signaling after EST-virus 
transduction may facilitate increased downstream promotion of AKT and CREB signaling. 
Moreover, as discussed in section 2.1,   the induction of SREBP1c and its target genes is 
promoted by C/EBPα induced insulin signaling, which would explain the increased lipogenic 
mRNA signaling [115, 116].  Collectively, these changes can synergistically enhance lipid 
droplet formation and lipid accumulation, and therefore can also cause the reverse effect shown 
when we knock down EST.  In the next chapter we will mechanistically evaluate the link 
between EST, estrogen signaling and adipogenesis in our cell culture model.  We will evaluate 
changes in coactivator recruitment, or squelching (1.2.4   Nuclear Receptors and Coregulators in 
Nuclear Receptor Pharmacology), that may determine the extent of PPARγ and PPARγ target 
gene activation in the presence of estrogen or lack thereof.  Additionally, we will discuss the role 
that estrogen signaling traditionally exerts over AKT,CREB, and ERK signaling and evaluate 
why we have observed changes in these signaling molecules which are inconsistent with 
literature data.  
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3.0  CHAPTER III: PHARMACOLOGIC INHIBITION AND KNOCKDOWN OF 
ERα IN OBESE PATIENTS ENHANCES ADIPOGENESIS AND LIPOGENESIS 
 
3.1 BACKGROUND 
The primary role of EST is to inhibit estrogen signaling; our results from the previous chapter 
strongly suggest that the changes in estrogen signaling mediated by EST over-expression or 
knockdown cause the promotion or attenuation of adipogenesis and lipogenesis, respectively. For 
more information on estrogen signaling in adipocytes see section 1.2.2 ERα/β. It is known that 
the ERα/β are expressed in preadipocytes and adipocytes, and that ERα typically mediates 
signaling involved energy metabolism and adipose tissue accumulation [44], therefore we 
decided to verify the presence and function of ERα in our cell culture model. Additionally, we 
will mechanistically evaluate the link between EST, estrogen signaling and adipogenesis in our 
cell culture model. 
 
 
 
 
 
 
 
 
78 
 
3.2 METHODS 
3.2.1 Patient Population 
ASC and adipose tissue collection:  Human adipose-derived stem cells (ASCs; primary 
preadipocytes) and whole fat/lipoaspirate were obtained through the Adipose Stem Cell Center, 
Department of Plastic Surgery, University of Pittsburgh. The whole fat or liposuction aspirates 
were collected from the abdominal subcutaneous fat of 18 female patients who were nondiabetic 
nonsmokers and ranged in age from 32 to 59 years. Subsequently, preadipocytes were isolated 
from the abdominal subcutaneous fat of these 18 patients [15 obese patients and 3 nonobese 
(lean) patients]. For linear regression analysis, 16 additional obese patients’ whole fat or 
lipoaspirate was analyzed. All experiments were performed on cells from the obese patients 
except as otherwise specified. The names of the patients were kept anonymous, and all patients 
used for preadipocyte differentiation experiments were female, nondiabetic nonsmokers and 
ranged in age from 25 to 56 years. The cells were cultured under standard conditions as reported 
previously. Briefly, cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F-12 
medium containing 10% standard fetal bovine serum (FBS) and 1% penicillin-streptomycin 
(Pen-Strep). Each cell line was cultured for no more than four passages. Patient 
sample and data collection were performed in accordance with the University of Pittsburgh 
Institutional Review Board Protocol PRO12050016. 
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3.2.2 Creation and Characterization of Lentivirus to Knockdown ERα   
To generate lentivirus expressing short hairpin RNAs (shRNAs) against ERα (shERα), 
expression plasmids containing shERα were purchased from Open Biosystems (Pittsburgh, PA). 
For each knockdown, five sequences were purchased and tested in transient-transfection assays. 
In this assay 0.2ug pCMX-ERα was transfected into 293T cells, followed by 2ug of one of the 5 
plasmids purchased (10:1 knockdown constructs: pCMX-ERα); the sequence with the most 
efficient knockdown was chosen for lentiviral production (Fig 43). A scrambled shRNA (shSCR) 
plasmid was purchased to serve as a control. Plasmid sequences for shERα can be found in 
APPENDIX A.  Lentiviral particles were generated using the second generation lentiviral system 
as described previously.               
 
  
Figure 43 ERα Knockdown (KD) Functional Assay 
293T cells were plated in 6 wells plates and grown to 80% confluency.  Duplicate co-
transfections were performed with 0.2ug pCMX-ERα, 2ug pCMX-pl2 (empty vector), 2ug 
scrambled or knockdown plasmids when applicable. For ERα KD, plasmid 2 was chosen for 
virus production. Sequences can be found in APPENDIX A.   
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3.2.3 Adipocyte Culturing and Differentiation  
In all experiments except those in which exogenous estrogen (E2) was added, differentiation 
medium 1 (DM1) consisted of DMEM/F-12 medium, 10% standard FBS, 1% Pen-Strep, 33uM 
biotin, 100 nM insulin, 17 uM pantothenic acid, 0.5 mM methylisobutylxanthine,1 uM 
dexamethasone, and 1 uM rosiglitazone. Differentiation medium 2 (DM2) consisted of 
DMEM/F-12 medium, 10% FBS, 1% Pen-Strep, 1 uM dexamethasone, and 100 nM insulin. 
Confluent preadipocytes were cultured in DM1 for 3 days before being switched to DM2 for 2 
weeks to reach terminal differentiation. Culture medium was changed every other day. For 
differentiation experiments in which E2 was exogenously added, the cells were cultured in 
phenol red-free DMEM/ F-12 medium and dextran-coated charcoal (DCC)-stripped FBS before 
the addition of E2 at a final concentration of 10 nM. 
3.2.4 Gene Expression Analysis  
Total RNA from preadipocytes/adipocytes was isolated using TRIZOL (Invitrogen) reagent. 
Total RNA from whole fat tissue or lipoaspirate was collected using the RNEASY Lipid Tissue 
Mid-Kits (Quiagen). The cDNA was synthesized from 1.0 ug of total RNA by Iscript from Bio-
Rad(Hercules, CA). Aliquots of cDNA were amplified on an ABI 7300 Real-Time PCR System 
from Applied Biosystems (Foster City, CA) using the SYBR green PCR master mix. mRNA 
expression was normalized against the expression of cyclophilin or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). A complete list of primers used can be found in APPENDIX A. 
Primers were validated using serial dilutions (1fg -10ng) of linearized expression vectors for the 
target gene or quantified cDNA from differentiated adipocytes to generate efficiency curves.  An 
example of an efficiency curve validating the EST primer can be found in APPENDIX A.  
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3.2.5  Oil Red O Staining and Quantification 
Differentiated six-well culture dishes were washed twice with cold phosphate-buffered saline 
(PBS) and then prefixed for 1 h with 10% formaldehyde in PBS. After 1 h, fresh 10% 
formaldehyde was added, and the cells were incubated overnight at room temperature. The next 
day, the cells were washed twice with PBS and then incubated in 60% isopropanol for 5 min, 
followed by drying at room temperature (RT). Cells were incubated with oil red O working 
solution for 10 minutes and then washed five times with deionized water. Images were acquired 
microscopically. For quantification of oil red O staining, cells were differentiated in triplicate in 
24-well plates, stained with oil red O, and eluted with 100% isopropanol, and 100 uL of elute 
was loaded onto 96-well plates. Absorbance was measured at 500 nm using a PerkinElmer plate 
reader. 
3.2.6 Western Blot Analysis  
Cells were lysed with NP-40 lysis buffer containing protease inhibitors and then quantified for 
protein concentrations by a bicinchoninic acid (BCA) assay kit from Pierce (Rockford, IL). 
Protein samples were resolved by electrophoresis on 10% SDS-polyacryl-amide gels. For the 
detection of insulin receptor substrate 1 (IRS1) and its phosphorylation, cell lysates were 
immunoprecipitated with an IRS1 antibody before being subjected to Western blotting using an 
IRS1 antibody and phosphotyrosine antibody. After transfer of proteins to polyvinylidene 
difluoride (PVDF) membranes, the membranes were probed with antibodies against total 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) (catalog no. sc94; Santa Cruz), phospho-
ERK1/2 (catalog no.sc7383; Santa Cruz), total AKT (catalog no. 9272; Cell Signaling), phos-
pho-AKT (catalog no. 9215; Cell Signaling), phospho-CREB (catalog no.87G3; Cell Signaling), 
total CREB (catalog no. 48H2; Cell Signaling), human EST (catalog no. SAB1400267; Sigma), 
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ERα (catalog no. sc7207;Santa Cruz), IRS1 (catalog no. 2382S; Cell Signaling), and 
phosphotyrosine (catalog no. ab10321; Abcam). Detection was achieved by using an ECL 
system from Amersham (Piscataway, NJ). Quantification was performed using the NIH ImageJ 
software. 
3.2.7 Transient Transfection Assay 
HepG2 cells or 293T cells were plated at a density of 2 x 106 cells per 48-well plate and 
incubated overnight. Transfection was performed using Trans-IT reagent from Mirus. Plasmids 
that were used in triplicate at an amount of 300 ng included pCMX-EST, pCMX-EST AAK, 
pCMX-ERα, pCMX-PPARγ, and pCMX. The triplicate plasmid amounts for pCMX-CBP, 
pCMX–β-Gal (where β-Gal is b-galactosidase), and tk-ERE-Luc (where ERE is estrogen 
response element Luc is luciferase) or tk-PPRE-Luc (where PPRE is peroxisome proliferator 
response element) were 50 ng, 200 ng, and 600ng, respectively. Cells were transfected and 
incubated for 24 h. Transfected cells were treated with the appropriate ligand for 24hrs using 
DMEM without phenol red and DCC FBS, followed by lysis and assays for luciferase and β-Gal 
activities. The luciferase activities were normalized to β-Gal activities. 
3.2.8 Chromatin Immunoprecipitation (ChIP) Assay 
Chromatin immunoprecipitation (ChIP) was performed according to a standard protocol (16). In 
brief, preadipocytes were plated in duplicate six-well plates, infected with either the vector or 
EST-expressing virus (here, EST virus), grown to confluence, and differentiated. Cross-linking 
was performed by the addition of formaldehyde, followed by sonication to shear the DNA. 
Immunoprecipitation was performed using an anti-PPARγ antibody (catalog no. ab45036) from 
Abcam, followed by elution using protein A magnetic beads (catalog no. S1425S) from NEB 
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(Ipswich, MA). Duplicate eluates and 2% of the input DNA were amplified by RT- PCR, and the 
PCR products were resolved on a 1% agarose gel. Quantification was performed by using the 
NIH ImageJ software. Fold enrichment was calculated as precipitated DNA versus input DNA. 
3.2.9 Statistical Analysis  
When applicable, results are presented as means ± standard deviations (SD) The Student t test 
was used to compare means of two groups and One-way ANOVA was used to compare the 
means of three or more groups. P values of less than 0.05 are considered to be significant. 
Repeated- measures ANOVA was used to compare means of two or more groups across multiple 
time points(MTT cell proliferation assay).  Linear regression analysis was performed using the 
Graph-Pad Prism software. 
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3.3 RESULTS 
3.3.1 Analysis of Estrogen Receptor Expression, Estrogen Response and Estrogen 
Treatment in Obese Preadipocytes  
We performed Western blots to probe for the presence of ERα in untreated preadipocytes and 
adipocytes, as well as vector and EST-virus treated adipocytes (Fig 44A). We found that ERα 
was expressed equally in all four conditions. Additionally, we verified that ERα was functionally 
active in our cell model by culturing vector and EST virus transduced cells in media containing 
dextran coated charcoal stripped (DCC) FBS with or without 10nM E2, and analyzed the 
response of ERα target genes; Insulin like growth factor binding protein 2 and 4 (IGFBP2 and 
4), as well as Glutathione Peroxidase 3 (GPX3) [131-133]. We found that in vector virus 
transduced cells, E2 treatment caused a marked induction of said E2 response genes; however 
EST virus transduced cells showed no activation after E2 treatment (Fig 44B), confirming the 
functional response of both ERα and EST (Fig 44B). Interestingly, we also observed that EST 
marginally retained its adipogenesis promoting characteristics in cell culture media formulated 
with DCC-FBS (Fig 44C).   
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Figure 44.  ERα is expressed in preadipocytes/adipocytes  
(A) Total lysate was collected from untreated preadipocytes and adipocytes, as well as vector 
and EST-virus treated adipocytes. NT, no transduction (virus) (B) Vector and EST virus 
transduced cells were cultured in DMEM without phenol red containing DCC- FBS and grown to 
confluency. Cells were treated for 24 hours in with 10nM E2 or vehicle. Total RNA was 
collected for RT-PCR analysis of ERα target genes. (C) Vector and EST virus transduced cells 
were cultured in DMEM without phenol red containing DCC- FBS and grown to confluency and 
differentiated for 14 days. Total RNA was collected for RT-PCR analysis of adipogenic genes.  
*, P < .05; **, P <.01; ns, not statistically significant compared to vector. 
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3.3.2 Pharmacologic Inhibition of ERα Increases Adipogenic Gene Expression  
In the previous section we established the expression and function of ERα and estrogen signaling 
in our preadipocytes/adipocytes. As described in the introduction (Section1.2.2 ERα/β) the 
attenuation of estrogen signaling shown  in  knock -out animal models [55], post-menopausal 
women[59], and rare mutations in the aromatase gene have led to increased adipose tissue 
accumulation and obesity [61]. In chapter 2, the over-expression of EST strongly inhibited 
estrogen signaling and lead to increased expression of adipogenic and lipogenic mRNA, and 
promoted the formation of lipid droplets; whereby the opposite effect is seen when we 
knockdown the expression of EST, most likely because of increased bioactive estrogen and 
increased estrogen signaling. We decided to test if this could be recapitulated when we cultured 
and differentiated our preadipocytes in the presence of a pharmacologic inhibitor of ERα. We 
decided to use the ERα antagonist Fulvestrant/Falsodex (ICI 182, 780 Tocris Bioscience). 
Fulvestrant is an estrogen receptor antagonist that competitively binds to the estrogen receptor 
and down-regulates the ER protein in human breast cancer cells; it is used clinically to treat post- 
menopausal women with estrogen receptor dependent metastatic breast cancer [134, 135].    
We used the preadipocytes from the initial EST over-expression experiment to conduct the ERα 
inhibitor studies. Once again, four patients’ preadipocytes were treated with vector or EST-virus 
and differentiated in media with Fulvestrant (ICI) or vehicle. We used RT-PCR to analyze 
changes in gene expression resultant of the ICI treatment. We did indeed find that Fulvestrant 
(ICI) increased the adipogenic mRNA expression of vector- virus transduced cells nearly to 
levels identical with vehicle treated EST-virus transduced cells (Fig 45). Additionally, we did not 
find significant additional promotion of adipogenic mRNA in Fulvestrant treated EST-virus 
transduced cells (Fig 45).   
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Taken together these results indicate that pharmacologic antagonism of ERα is sufficient to 
promote adipogenesis at the genetic level; additionally these results suggest that the modulation 
of estrogen signaling by EST causes the promotion of adipogenesis.  
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Figure 45. Pharmacologic antagonism of ERα can promote adipogenic mRNA expression  
Preadipocytes were transduced with vector or EST-expressing lentivirus, then were cultured and 
differentiated in standard medium with Fulvestrant (100nM) or vehicle for 14 days. (A) Total RNA was 
extracted before and after differentiation, and the expression of indicated adipogenic genes was 
measured by real-time PCR. *, P < .05; **, P <.01; ns, not statistically significant compared to 
vector. 
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3.3.3 Pharmacologic Inhibition and Knockdown of ERα Increases Adipogenic and 
Lipogenic Gene Expression  
 
Our results from the previous section provided the impetus to compare the pharmacologic 
inhibition of ERα to genetic knockdown of ERα. For this experiment we used two patients’ 
preadipocytes and treated them with vector or EST virus and additionally with shSCR or shERα 
virus or Fulvestrant (ICI). We confirmed that vector virus treated cells that were either 
transduced with shERα or ICI achieved the same promotion of adipogenic and lipogenic mRNA 
expression as vehicle treated EST-virus transduced adipocytes (Fig 46B-C). Also, we did not see 
significant additional promotion of adipogenesis or lipogenesis in EST- virus transduced cells 
treated with Fulvestrant (ICI) or transduced with shERα (Fig 46B-C). Taken together, these 
results confirm that EST can promote or inhibit adipogenesis and lipogenesis by directly 
mediating the ERα signaling pathway.   
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Figure 46. Antagonism and Genetic Knockdown of ERα promotes adipogenic mRNA 
expression. Preadipocytes were transduced with vector or EST-expressing lentivirus and 
additionally with shSCR or shERα-virus. Cells were then were cultured and differentiated in 
standard medium with Fulvestrant (100nM) or vehicle for 14 days.  (A) Cells lysates were analyzed 
for the expression of ERa after knockdown. Total RNA was extracted before and after 
differentiation, and the expression of indicated (B) adipogenic genes or (C) lipogenic genes was 
measured by real-time PCR, (n=2). *, P < .05; **, P <.01; ns, not statistically significant 
compared to vector. 
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3.3.4 Pharmacologic Inhibition and Knockdown of ERα Increases Lipid Droplet 
Accumulation  
 
We also quantified lipid droplet formation from the two aforementioned patients’ adipocytes. In 
addition to the promotion of adipogenic and lipogenic mRNA expression, the genetic 
knockdown or antagonism of ERα also enhanced lipid droplet formation and lipid accumulation 
as measured by oil red O staining and quantification(Fig 47). In shERα - vector cells or vector 
cells treated with ICI, the quantified oil red O concentration (OD) was equal to EST transduced 
cells. We did not find any additional promotion of lipid droplet formation in EST transduced 
cells treated with the ICI compound or transduced with shERα.  
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Figure 47. Knockdown or Antagonism of ERα Increases Lipid Droplet Formation and 
Lipid Accumulation. Preadipocytes were transduced with vector or EST-expressing lentivirus 
and additionally with shSCR or shERα-virus. Cells were then were cultured and differentiated in 
standard medium with Fulvestrant (100nM) or vehicle for 14 days. (A) Cells were then stained with 
oil red o dye, and examined microscopically as well as quantitatively, (n=2). *, P < .05; ** , P 
<.01; ns, not statistically significant compared to vector; OD500, optical density at 500nm.  
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3.3.5 Pharmacologic Inhibition and Knockdown of ERα Increases AKT and CREB 
signaling  
 
Additionally, we tested if the antagonism or genetic knockdown of ERα could also affect insulin 
signaling in a manner similar to EST over-expression.  We found that in vector treated cells, 
knockdown of ERα or antagonism with the ICI compound increased AKT and CREB signaling 
commensurate to that seen in the EST over-expression cells treated with vehicle or transduced 
with shSCR.  Additionally, there was no increase in AKT or CREB signaling in the EST-shERα 
transduced cells or EST transduced ICI treated cells.  
 
 
 
 
 
 
Figure 48. Knockdown or Antagonism of ERα Increases AKT and CREB Signaling. 
Lysates from Preadipocytes  transduced with vector or EST-expressing lentivirus and 
additionally with shSCR or shERα-virus and cultured and differentiated in standard medium with 
Fulvestrant (100nM) or vehicle for 14 days were subjected to Western blot analysis to detect protein 
expression of (A) ) total AKT, phospho-AKT (p-AKT), total CREB, and phospho-CREB (p-
CREB). The signals were quantified by using NIH ImageJ software.(n=2) *, P < .05; ** , P 
<.01; ns, not statistically significant compared to vector. 
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3.3.6   Molecular mechanism for the inhibitory effect of the estrogen-ER signaling pathway 
on adipogenesis:  Luciferase Assay and Chromatin Immunoprecipitation  
 
As stated in the introduction (1.2.3 Nuclear receptor coactivators), the regulation of nuclear 
receptor transcriptional activation after ligand binding largely depends on the recruitment of 
coactivators to the ligand binding domain or AF2 domain [81].  The recruitment of coactivators 
enhances the ability of nuclear receptors to bind to their specific DNA motif known as a 
hormone response element [82]. Many nuclear receptors share and compete for coactivators 
subsequent to ligand binding. This competition is known as “crosstalk”, whereby the activation 
of one nuclear receptor and its signaling pathway can inhibit the activation of another nuclear 
receptor and its pathway [41].  It has been established that crosstalk between nuclear receptors is 
an important regulatory mechanism that can fine-tune transcriptional activation or repression of 
specific nuclear receptor target genes [87].  
ERα and PPARγ both share the coactivator CREB binding protein (CBP) [136, 137]. CBP 
contains histone acetylase activity that allows for potent transcriptional activation of each NR’s 
target genes. We used a transient transfection and luciferase reporter gene assay to show that 
ERα inhibited the PPARγ mediated activation of a PPAR-responsive reporter gene, tk- 
PPRE-Luc, in a ligand-dependent manner; however this inhibition was attenuated by the co-
transfection of CBP (Fig 49). Reciprocally, PPARγ  inhibited the ERα mediated activation of an 
ER responsive reporter gene, tk-ERE-Luc, in a ligand-dependent manner, and this inhibition was 
abolished by the co-transfection of CBP. Taken together, these results demonstrate that the 
coactivator CBP plays an integral role in the transcriptional activation of both PPARγ and ERα. 
Finally, crosstalk between ERα and PPARγ is directly influenced by CBP’s abundance or lack 
thereof.   
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Figure 49.  Nuclear Receptor Co-Activator CBP can Rescue ERα/PPARγ Crosstalk Effect.  
(A and B) 293T cells were transfected with either the tk-ERE-Luc reporter gene together with 
ERα and/or CBP (A) or the tk-PPRE-Luc reporter gene together with PPARγ and/or CBP (B). 
Transfected cells were treated with E2 (10 nM) and/or rosiglitazone (Rosi; 1 uM) for 24 h before 
luciferase assay. The luciferase activities were normalized against β-Gal activities from the co-
transfected β-Gal vector. Results are shown as fold induction over vehicle-treated triplicates. *, P 
< .05; ** , P <.01; ns, not statistically significant compared to vector. 
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Based on the results of the luciferase assay, we decided to use a chromatin immunoprecipitation 
assay (ChIP)  to biochemically analyze the effect that E2 or ICI treatment had on the binding of 
PPARγ to the promoter region of its target genes LPL and aP2. Preadipocytes were transduced 
with vector or EST-virus and differentiated for two weeks in standard media containing ICI or 
E2.  Here we showed that in vector-virus transduced cells, ICI treatment enhanced PPARγ 
binding to levels commensurate with EST transduced vehicle treated cells; while E2 treatment 
attenuated PPARγ binding in vector virus transduced cells (Fig 50). The binding of  PPARγ  was 
enhanced in EST virus transduced cells and they remained unaffected by E2 treatment which is 
consistent with the  increased adipogenic effect (Fig 50).  Taken together, these results show that 
EST can promote adipogenesis through direct inhibition of estrogen signaling and indirect 
transcriptional activation of PPARγ. The over-expression of EST inhibited E2-ERα activation, 
which promoted CBP enhanced recruitment of PPARγ to the promoter region of its targets genes 
and subsequent activation of these genes.    
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Figure 50. CHIP Assay showing the effect of E2/ICI treatment on the recruitment of 
PPARγ to the promoters of two of its adipogenic target genes LPL and aP2  
The vector- or EST-transduced preadipocytes were treated with 100nM fulvestrant (ICI) or 10 
nM E2 and then induced to differentiate for 2 weeks before being evaluated for the recruitment 
of PPARγ onto the LPL (left panel) and aP2 (right panel) gene promoters by chromatin 
immunoprecipitation (ChIP) assay.(n=2) Quantification was performed by using NIH ImageJ 
software. *, P < .05; ** , P <.01; ns, not statistically significant compared to vector. 
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3.3.7 Linear Regression Analysis of ERα, ERβ, EST Gene Expression versus Body Mass 
Index from whole fat or lipoaspirate of Obese Patients  
 
The pro-adipogenic effect of EST over-expression combined with the anti-adipogenic effect of 
estrogen signaling provided the impetus for us to examine if a correlation existed between the 
expression of EST or ERα and BMI. We isolated total RNA from whole fat or lipoaspirate from 
16 obese patients and used RT-PCR and linear regression to analyze the expression of EST and 
ERα compared to BMI. We found a positive and significant correlation between the expression 
of EST and BMI; additionally we found that there was an inverse and significant correlation 
between the expression of ERα and BMI (Fig 51). Taken together, these results provide 
physiological evidence that the mRNA expression of EST and ERα has a significant and 
functional effect on adiposity in the cohort studied in our experiments. It should be noted that the 
initial depiction of these results were confusing on the surface due to the fact that a higher CT 
value indicated lower  mRNA expression and vice versa. Therefore, we multiplied the final CT 
values by (-1) in order to present the results in a way that the slope of the linear regression line 
matched the correlation (Fig 51).  
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Figure 51.  Linear Regression of Whole Fat/ Lipoaspirate EST, ERα, ERβ, mRNA 
Expression 
Total RNAs extracted from whole fat or lipoaspirate of a cohort of 16 obese patients were 
subjected to gene expression analysis by real-time PCR. The correlation between body mass 
index (BMI) and EST (A-B), ERα (C-D), or ERβ (E-F) gene expression was analyzed by linear 
regression analysis. The expression levels of EST and ERs were presented as normalized 
threshold cycle values, in which a higher threshold cycle value indicates low gene expression. 
The expression is normalized to GAPDH.  To avoid confusion, the normalized CT values were 
multiplied by (-1) so that the slope of the linear regression line matched the correlation.  
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3.4 DISCUSSION 
We have identified a mechanistic paradigm which describes the novel role for EST in human 
adipogenesis. In the previous chapter we demonstrated that EST over-expression leads to 
increased adipogenesis and lipogenesis, while EST knock down causes the opposite effect.  In 
this chapter, our goal was to gain a mechanistic understanding of the observations shown in the 
previous chapter. Here we summarize the major findings in this chapter:  
(1) Pharmacologic inhibition or genetic knockdown of ERα  in preadipocytes/adipocytes can 
recapitulate the same adipogenic and lipogenic promoting effects seen when 
preadipocytes are transduced with EST over-expression virus (Fig 48).  
(2) Estrogen signaling antagonizes PPARγ signaling and vice versa through squelching or 
coactivator competition for CBP ( Fig 49). Moreover, EST directly inhibits estrogen 
signaling which indirectly increases the binding of PPARγ to the promoters of its target 
genes (LPL, aP2) (Fig 50) 
(3) Pharmacologic inhibition or genetic knockdown of ERα in preadipocytes/adipocytes can 
increase terminal AKT and CREB protein expression commensurate to that seen in EST 
overexpression cells (Fig 48).  
(4) In whole fat or lipoaspirate, we observed a positive correlation between EST mRNA 
expression and BMI in 16 obese patients. Additionally, we found an inverse correlation 
between ERα mRNA expression and BMI (Fig 51).  
In this chapter our main focus was to understand the connection between EST, estrogen 
signaling, and the activation of PPARγ and its target genes leading to the promotion of 
adipogenesis and lipogenesis. We showed that the ERα was present and functional in our 
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adipocytes and preadipocytes, and that virus treatment did not adversely affect the protein 
expression of the ERα (Fig 44).  
To gain a better understanding of the global nature of estrogen antagonism in adipogenesis, we 
added a pharmacologic inhibitor of ERα/β (Fulvestrant, ICI), to our standard differentiation 
media. After 14 days in cell culture, we found that vector cells treated with the inhibitor also 
displayed a significant augmentation of adipogenesis that was commensurate to EST-virus 
transduced cells (Fig 47). This was a clear indication that targeting the estrogen signaling 
pathway, either the substrate or the receptor, caused significant changes in adipose tissue 
development. We used lentivirus expressing shRNA to knock down ERα (shERα) to confirm 
that changes in ERα signaling, as opposed to ERβ, caused the observed adipogenesis promoting 
effects.   Again, we found increased mRNA expression of adipogenic and lipogenic genes, as 
well increased AKT and CREB signaling (Fig 48); all of which were comparable to that seen in 
EST-virus transduced cells.  
We know that because both ERα and PPARγ are nuclear receptors, the possibility that they 
shared coactivators is very high. In fact it was reported in several papers that both ERα and 
PPARγ do share the coactivator CREB Binding Protein (CBP) [136, 137]. Based on this fact, we 
used transient luciferase and reporter gene assays to determine if PPARγ and ERα could 
antagonize each other in a ligand dependent manner and if this could be attenuated by CBP 
transfection. The luciferase assay confirmed that these two nuclear receptors can in fact 
antagonize each other in a ligand depend manner and this antagonism can be diminished by 
increased expression of CBP (Fig 49).  Moreover, we used a biochemical assay (ChIP) to show 
that EST can promote the recruitment of PPARγ to the promoters of its target genes by 
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antagonizing estrogen (Fig 50).  It is important to note that the increased induction of PPARγ 
target genes may also have a positive effect on the expression of PPARγ itself.  PPARγ is known 
as a “lipid sensor” because it can be activated by dietary fatty acids, and there metabolites [138]. 
LPL, the PPARγ target gene measured throughout this study, maintains a dual functional role as 
a triglyceride hydrolase and also as a bridging factor for heparan sulfate proteoglycan mediated 
lipoprotein uptake [35]. The increased induction of LPL subsequently can increase the 
intracellular concentration of fatty acids that are taken up from the media serum, thus providing 
increased stimuli for PPARγ gene expression.  
The mechanisms that caused increased AKT, CREB, and MAPK/ERK protein expression after 
EST overexpression/ERα antagonism/ERα knockdown, and the opposite after EST knockdown 
are still unclear.  Estrogen signaling has been reported to have an immediate effect on AKT and 
ERK/MAPK signaling that is mediated through non-nuclear mechanisms [45, 139].  In human 
endothelial cells, estrogen treatment caused a biphasic response. First, estrogen treatment 
facilitated the rapid release of intracellular calcium stores and marked increase in cytoplasmic 
calcium concentration leading to the activation of MAPK/ERK [140, 141]. The activation of 
MAPK was shown to be dependent on the ability of the ERα to mobilize and increase 
intracellular calcium signaling [140]. This was quickly followed by the activation of PI3 kinase.  
Mechanistically, the ERα has been shown to directly interact with the catalytic subunit (p85) of 
the PI3 kinase causing  increased phosphorylation of IRS1, recruitment and phosphorylation of 
the PI3 kinase and subsequent recruitment and phosphorylation of AKT [139, 142]. We would 
expect that in the EST and vector cells treated with insulin, the differential effect that loss of 
estrogen signaling (EST cells) would have on IRS1 and subsequent AKT and CREB signaling 
would be apparent immediately, however this was not the case (Fig 23). This result was actually 
103 
 
supported by findings from Simoncini et. al., that showed that E2 treatment did not have a 
potentiating effect on the IRS1, the PI3 kinase or AKT signaling in endothelial cells that were 
already stimulated by insulin [139].  Since we did not see a difference in rapid IRS1 signaling 
(proxy for PI3K signaling) but we did see a significant difference in AKT and CREB after 
terminal differentiation, this suggests that the effect of estrogen signaling or lack thereof in our 
cell culture model is actually a nuclear or genomic effect.  We can only speculate based on the 
observations made that it is most likely a result of increased PPARγ activation because PPARγ 
has the ability to induce C/EBPα and vice versa [34, 73]. This is important because the 
expression of C/EBPα is critical for proper insulin signaling during adipogenesis[21, 74]                       
(covered in the discussion  of chapter 2); therefore the downstream effects of enhanced C/EBPα 
induction most likely caused increased AKT/CREB signaling that were not apparent early in the 
adipogenic cascade (Fig 23 IRS-1) but became apparent in the later stages of adipogenesis 
(terminally differentiated AKT/CREB westerns).  It is plausible to extend the conclusion that the 
changes in PI3K/AKT and CREB signaling takes place through a genomic effect exerted by ERα 
and not the classical rapid signaling mechanism can also be extended to the changes that were 
observed in ERK signaling after terminal differentiation. We did not analyze the rapid activation 
of the MAPK pathway in our cell culture model but we did use an inhibitor of MAPK to test if 
the activation of this pathway was essential for the augmented adipogenesis seen in EST cells 
(Fig 25-27). The inhibitor did not have any effect on terminal differentiation which suggests that 
this also may be a secondary genomic effect that is attributed to the overall change in ERα and 
PPARγ activation at the genomic level.  It is also possible that the changes in AKT and 
MAPK/ERK signaling are mediated by the G- protein estrogen receptor (GPR30/GPER).  The 
GPR30 is a membrane bound GPCR localized to the endoplasmic reticulum that can bind 
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estrogen and mediate an estrogenic effect[143].  GPR30’s estrogenic effects can also be inhibited 
by the classical estrogen receptor antagonists Tamoxifen and Fulvestrant (ICI 182,780) [144, 
145]. GPR30 is expressed in a number of different mouse and human tissue types including 
brain, ovary, prostate, lung, endothelial and adipose tissue [145, 146]. Functionally, it has been 
shown that  GPR30  is an integral mediator of many signal transduction pathways involved in the 
maintenance of the cardiovascular system, neuroendocrine and endocrine system, and is involved 
in the regulation of energy homeostasis and bod weight maintenance [143, 145-147]. Whilst still 
controversial, GPER30 KO causes sexual dimorphic changes in obesity, energy expenditure, and 
body weight in male and female mice [145]. Additionally, many of the secondary messenger 
signaling pathways that were mentioned  in the previous paragraph and were once attributed 
exclusively to ERα, have now been shown to additionally or exclusively actually involve GPR30 
[143]. More specifically, the rapid non genomic signaling pathways that activate MAPK/ERK 
and subsequently PI3K and AKT are emerging as GPR30 mediated pathways.  It was shown in 
ER negative  SKBR3 breast cancer cells that E2 treatment led to the rapid activation of  
MAPK/ERK pathway through GPR30, and culminated with c-fos expression [148].  In COS7 
and SKBR3 cells it was shown that estrogen treatment could activate GPR30 leading to the 
phosphorylation of the PI3K and subsequent nuclear membrane accumulation of 
phosphatidylinositol 3,4,5-trisphosphate (PIP3 ) molecules and finally accumulation and 
activation of Akt [149]. GPR30 is expressed in mouse adipose tissue, however it is not known if 
it is also expressed in human adipose tissue [145].  It is possible that the non-genomic effects that 
we have observed in AKT and MAPK signaling in our cell culture models could be attributed to 
GPR30 mediated cell signaling. While the rapid effects mediated by GPR30 have been 
established in several cell culture models, the slower signaling that we evaluated in terminally 
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differentiated adipocytes remains unclear albeit a provocative explanation to the observations 
seen in our experiments.  
Lipogenic gene expression was also evaluated in this document.  Increased expression of 
lipogenic genes was observed in EST overexpression cells as well as  
ERα knockdown/pharmacologic inhibition studies. As aforementioned in the chapter 2 
discussion, SREPB1c promotes lipogenic mRNA signaling (ACC, FASN, and SCD1); moreover 
it is activated by increased insulin sensitivity and signaling [115, 116]. Our results suggest that 
the increased AKT/CREB signaling, which is mediated by increased C/EBPα signaling, led to 
the enhanced lipogenic signaling facilitated by SREBP1c.  
These experiments have provided a clear picture as to the role of EST in human adipogenesis. In 
general our data suggests that EST serves as mediator of estrogenic effects in subcutaneous 
adipose tissue. Specifically, in subcutaneous adipocytes estrogen has an overall inhibitory effect 
on adipogenesis and lipogenesis; EST has the ability to mitigate that effect.  During the early 
stages of adipogenesis EST is highly expressed and therefore able to deactivate estrogen and 
inhibit the repressive effects facilitated by estrogen signaling. This promotes increased activation 
of PPARγ and PPARγ target genes thus facilitating adipogenesis. As the adipogenic process 
begins to wane, the expression of EST decreases to allow the repressive effects of estrogen 
signaling to return and moderate the level of mature adipocyte development.  The EST-Estrogen 
signaling pathway thus serves to facilitating proper induction of adipogenic genes to develop 
functional adipocytes, while simultaneously protecting adipocytes from an over stimulation of 
adipogenic genetic signaling. A general mechanism of EST action in adipogenesis is depicted in 
(Fig 52).  
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Finally, since we did not have a suitable animal model, we isolated RNA from whole fat or 
lipoaspirate from a cohort of obese patients and observed that in mature adipocytes the mRNA 
expression of EST positively correlates with BMI. Additionally, the inverse correlation of ERα 
mRNA expression, which is complementary to other data found in the literature, supported our 
experiments in cell culture which showed the antagonism of estrogen signaling led to increased 
adiposity. We cannot conclude from this data that EST is sole cause for increased BMI, however 
this does provide a provocative indication that EST does have a major role in adipogenesis 
beyond what we found in cell culture.  
The overall limitations to this study include a small sample size and the fact that this was done 
entirely in cell culture with no in vivo model. Additionally, we found that cells taken from the 
abdominal region were most responsive and therefore we only included abdominal 
preadipocytes.  Although the effects of EST overexpression and knockdown were observed in 
preadipocytes isolated from both the obese and non-obese patients, we cannot exclude the 
possibility that age, menopausal status and steroid hormone level may confound our results.  
Finally, since overexpression of EST under the estrogen-free DCC cell culture condition can still 
marginally increase the expression of certain adipogenic marker genes (Fig. 44), we cannot 
exclude the possibility of an off-target effect due to the overexpression of EST, as well as the 
existence of additional EST substrates that may also have an effect on adipogenesis.  It should be 
noted that there are several limitations of this model to evaluate if EST mediated inhibition of 
estrogen signaling is the primary reason for increased adipogenesis in EST overexpression cells. 
For example, the stripped serum effectively removes all lipid molecules involved in cell 
signaling as well as many growth factors necessary for adequate differentiation. We did in fact, 
observe that these cells did not differentiate as robustly as the preadipocytes in STD-FBS (not 
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shown).  The stripped serum also removes other hormones involved in adipogenesis such as 
androgens, progesterone, and thyroid hormones. While these are not EST substrates they do play 
a role in adipogenesis and therefore could confound our results.  
 
 
 
Figure 52.  EST regulation of Adipogenesis and Lipogenesis  
The sulfation of E2 and inhibition of estrogen signaling, “tips the CBP scale” toward PPARγ 
facilitating increased activation of PPARγ and target genes.   
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4.0 CHAPTER IV: CONCLUSIONS AND PERSPECTIVES 
 
4.1 PHARMACEUTICAL POTENTIAL OF EST AS A DRUGGABLE TARGET 
Our findings are interesting when viewed in the context of weight loss, and speculation can be 
made as to whether EST is a viable druggable target for the reduction of body fat. It has been 
shown that in adult humans there is approximately a 10% annual turnover of adipocytes [103]and 
similar findings have been demonstrated in animal models[150]. Moreover the adipocyte number 
that each person contains is fixed in childhood and surprisingly even weight loss, which 
decreases the lipid volume per cell, does not decrease the set number of fat cells[101-103].  
Additionally, a randomized study of 36 non-obese pre-menopausal female patients whom had 
undergone liposuction showed that one year after surgery, body fat in both visceral and 
subcutaneous depots  had returned preferentially in the abdominal region[151].  
Traditional weight loss strategies have proven to be effective at reducing adipocyte size; 
however an increasing amount of data shows that this does not reduce adipocyte number. This 
may be the reason why in many cases weight loss attempts fail and any reductions are quickly re-
gained or even surpassed.  A new paradigm could revolve around the idea that an effective 
weight loss strategy should include a targeted approach to reduce adipocyte turnover by 
attenuating adipogenesis or increasing adipocyte death.  Adipocyte death has been shown to 
primarily closely resemble necrosis as opposed to apoptosis; it tends to include macrophage 
infiltration and inflammation that is worsened in obese individuals with high intracellular fat 
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content [152]. Several in vitro studies have analyzed the ability of naturally occurring 
compounds, such as resveratrol to induce cell death, however an in vivo model has not been 
analyzed[153]. Increased adipocyte death may be an attractive strategy, however rigorous in vivo 
testing is necessary to ensure that the increased inflammatory response does not worsen 
individual health outcomes.  
An inhibition of adipogenesis may be a safer strategy to increase to stave off the re-accumulation 
of adipose tissue after weight loss. We showed in Figure 9 that EST protein is expressed highest 
at the beginning of adipogenesis and begins to diminish towards the end of differentiation.   It is 
plausible to speculate that an EST inhibitor given locally after weight loss surgery or during and 
intense weight loss period could essentially “re-calibrate” the adipocyte number set point. Some 
caveats to this approach are the apparent reduction of insulin signaling we observed after EST 
knockdown. Whilst we were not able to pinpoint a mechanism for the changes observed in 
AKT/CREB signaling, it has been shown in conditional PPARγ knockout murine models that 
loss of PPARγ signaling in adipose tissue leads to hepatic insulin resistance[154]. Since loss of 
PPARγ signaling is the suspected mechanism that causes an attenuation of adipogenesis in the 
EST knockdown cells, this strategy should also be met with caution.  
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4.2 HUMAN AND MOUSE SPECIES- SPECFIC DIFFERENCES IN THE 
REGULATION OF ADIPOGENESIS BY EST 
These studies were primarily driven by the results from previous publications conducted in our 
lab and others using murine animal models as well as primary and stable mouse cells lines. 
Several key differences in the regulation of EST were found between mice and humans which 
we will highlight here. Overall, the results from mouse studies demonstrated that in female mice 
Est is a negative regulator of adipogenesis; in primary adipocyte cell cultures the over-expression 
of Est inhibited adipogenesis and knockdown enhanced it [3, 18]. Moreover this was associated 
with decreased expression of PPARγ, LPL and FAS [18].  This of course is the opposite of the 
regulation identified here in humans.  Moreover, in mice, it was found that the repressive effect 
from the over-expression of Est coincided with a loss of Akt signaling and sustained Erk 1/2 
expression during terminal differentiation [3]. Based on the results from the mouse study we 
concluded that the repressive effect found when we over-expressed EST was mediated by the 
inability of these cells to activate Akt signaling and instead maintained sustained activation of 
Erk 1/ 2 [3]. Additionally, when we treated murine EST and vector cells with physiological 
concentrations of E2, we found no reduction in adipogenesis in the vector cells, nor did we 
observe any change in adipogenesis in the Est cells [3]. Finally, in the mouse study we were not 
able to elucidate a direct mechanism, such as a substrate other than E2 that linked Est to the 
changes in Erk, Akt, or the adipogenic gene expression [3].   
In humans the over-expression of EST increased both AKT and ERK 1/2 while knockdown of 
EST inhibited both of these signaling molecules. Additionally, we found that in humans when 
vector cells were treated with E2 this caused marked reductions in adipogenic gene expression 
and lipid droplet formation but EST cells were protected.  Mechanistically we found that 
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estrogen-induced inhibition of adipogenesis was caused by coactivator competition for CBP 
between ERα and PPARγ [88].   
The driving force behind the phenotype that we observed in the human study was the opposing 
effects estrogen signaling had on PPARγ [88].  In the mouse study we did not observe any effect 
attributed to estrogen signaling that altered adipogenesis. This does contradict many published 
articles which cite that E2 treatment in murine cell lines such as 3T3-L1 cells caused marked 
reduction in adipogenesis. The cause of this discrepancy is unclear, however we did cite that we 
only used physiological concentrations of E2 in our experiments [155], while many other 
published articles used supraphysiological concentrations of E2 or overexpressed ERα [57]. 
Since several studies relied on supraphysiological concentrations of estrogen, this suggests that 
in these cell lines the expression of ERα may be diminished compared to primary cells, such as 
those used in our model.  Differences in the way mice and humans metabolize estrogen could 
also be the cause of the discrepancy seen between mice and humans. Mice and human adipocytes 
express EST, Steroid sulfotransferase (STS) and Aromatase (CYP19A1) [3, 18, 20, 40, 43, 88, 
156, 157].  It is known that in addition to ERα and Erβ, GPR30 is expressed in mouse adipocytes 
[145], however it is not known whether GPR30 is expressed in human adipocytes. If estrogen 
can be metabolized by both ERα and GPR30 in mice but exclusively by ERα in humans this 
could be the reason why varying estrogen concentration had such a significant genomic impact 
(PPARγ and target genes) in human adipocytes but not in rodents.  The opposing role of EST in 
adipogenesis between humans and mice is also not well understood. Literature data consistently 
shows that in mice and humans, loss of estrogen signaling leads to increased adiposity [44, 54, 
56, 158-160], therefore it is interesting that several in vivo and in vitro studies have shown that in 
female murine models Est acts a negative regulator of adipogenesis [3, 18]; aP2-Est transgenic 
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mice over-expressing Est in adipocytes have decreased adipocyte size [18].  The mechanism 
through which Est exerts its negative effects on rodent adipogenesis has not been clearly defined 
in the publications detailing said observations. It is clear that local factors present in specific 
WAT depots must modulate the response to estrogen inactivation by EST. There is still the 
possibility that an unknown substrate for EST may exist. This is supported by our findings in Fig 
48 which show that in media lacking estrogen EST was still able to marginally enhance the 
expression of PPARγ and one of its target genes.   
In conclusion the true cause of species-species difference between human and mouse EST 
remains unknown; however additional experiments to elucidate an unknown substrate could be 
quite beneficial to our understanding of this enzyme.  
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APPENDIX A.   
Adipose Derived Stem Cell patients and Experiments  
 
 
Whole Fat Removal/Liposuction Patients  
BMI Age Sex Fat Depot 
28.7 53 F Abdominal 
23 35 F Abdominal 
22.2 43 F Abdominal 
27.7 44 F Abdominal 
32.9 34 F Abdominal 
30.5 43 F Abdominal 
30.2 53 F Abdominal 
29.6 59 F Abdominal 
28.1 34 F Abdominal 
28.3 50 F Abdominal 
33.7 39 F Abdominal 
       31.4 41 F Abdominal 
37.8 46 F Abdominal 
21.4 32 F Abdominal 
30 36 F Abdominal 
25.5 45 F Abdominal 
Patient number Sex Age BMI Fat depot Diabetic Experiments performed
1 F 30 28.1 Abdominal N Initial real-time PCR
2 F 31 50 Abdominal N Initial real-time PCR
3 F 56 31.3 Abdominal N Initial real-time PCR
4 F 33 29.9 Abdominal N Initial real-time PCR
5 F 40 24.7 Abdominal N Triclosan treatment, Dexamethasone Depletion 
6 F 43 32.5 Abdominal N Initial EST overexpression and 2nd EST overexpression with ICI treatment
7 F 44 27.7 Abdominal N Initial EST overexpression and 2nd EST overexpression with ICI treatment
8 F 34 32.9 Abdominal N Initial EST overexpression and 2nd EST overexpression with ICI treatment
9 F 25 29.5 Abdominal N Initial EST overexpression and 2nd EST overexpression with ICI treatment
10 F 50 28.3 Abdominal N shEST knockdown
11 F 37 32.3 Abdominal N shEST knockdown
12 F 52 26.6 Abdominal N PD98059 treatment
13 F 46 37.8 Abdominal N EST AAK mutant
14 F 45 25.5 Abdominal N shERa knockdown, ICI, EST Overexpression
15 F 34 28.1 Abdominal N shERa knockdown, ICI, EST Overexpression, CHIP Assay 
                     16 (Lean) F 47 21.8 Abdominal N EST Overexpression, shEST knockdown
                     17 (Lean) F 44 23.7 Abdominal N EST Overexpression, shEST knockdown
                     18 (Lean) F 32 21.4 Abdominal N EST Overexpression, shEST knockdown
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 pCMXpl2-hEST SEQUENCING RESULTS FROM THE UNIVERSITY OF 
PITTSBURGH GENOMICS CORE. 
Sequencing was done using the CMV promoter. The HINDIII sequence is highlighted in 
red followed by the EST sequence and flanked by NHE1 highlighted in orange.  The EST 
sequence was validated with NCBI and is highlighted blue.  
 
NNNNNNNNTCNNNNNCGGTNCCGGGCCCCCCCTCGAGAAGCTTATGAATTCTGAACTTGAC
TATTATGAAAAGTTTGAAGAAGTCCATGGGATTCTAATGTATAAAGATTTTGTCAAATATTG
GGATAATGTGGAAGCGTTCCAGGCAAGACCAGATGATCTTGTCATTGCCACCTACCCTAAAT
CTGGTACAACCTGGGTTAGTGAAATTGTGTATATGATCTATAAAGAGGGTGATGTGGAAAAG
TGCAAAGAAGATGTAATTTTTAATCGAATACCTTTCCTGGAATGCAGAAAAGAAAACCTCAT
GAATGGAGTAAAACAATTAGATGAGATGAATTCTCCTAGAATTGTGAAGACTCATTTGCCAC
CTGAACTTCTTCCTGCCTCATTTTGGGAAAAGGATTGTAAGATAATCTATCTTTGCCGGAATG
CAAAGGATGTGGCTGTTTCCTTTTATTATTTCTTTCTAATGGTGGCTGGTCATCCAAATCCTG
GATCCTTTCCAGAGTTTGTGGAGAAATTCATGCAAGGACAGGTTCCTTATGGTTCCTGGTAT
AAACATGTAAAATCTTGGTGGGAAAAGGGAAAGAGTCCACGTGTACTATTTCTTTTCTACGA
AGACCTGAAAGAGGATATCAGAAAAGAGGTGATAAAATTGATACATTTCCTGGAAAGGAAG
CCATCAGAGGAGCTTGTGGACAGGATTATACATCATACTTCGTTCCAAGAGATGAAGAACA
ATCCATCCACAAATTACACAACACTGCCAGACGAAATTATGAACCAGAAATTGTCGCCCTTC
ATGAGAAAGGGAATTACAGGAGACTGGAAAAATCACTTTACAGTAGCCCTGAATGAAAAAT
TTGATAAACATTATGAGCAGCAAATGAAGGAATCTACACTGAAGTTTCGAACTGAGATCTAA
GCTAGCTAGGTAGCTAGAGGATCTTTGTGAANNAANCNTTACTTCTGNGGTGTGACATNANT
NGGACAAACTACCTACAGAGATTTNAAGCTNTNNNGNAAATNNNAANNTTTTNNGNGNNNN
NGNNNNNACTACNGANNCTNNNNNTNNNNNNNNTNNNNANNNNNNNTNGNNANCTNANNN
NNNNGNGNNCNNNNNNNNGNNNNNNNNNNNNNNAAANNNNNTTNGCNNNCN 
pWPI-EST SEQUENCING RESULTS FROM THE UNIVERSITY OF PITTSBURGH 
GENOMICS CORE 
Sequencing was done using the EF1 alpha promoter primer, however it did not sequence 
the full length EST.  The 5’ Restriction enzyme PME1 followed by the EST sequence was 
confirmed. PMEI restriction enzyme sequence highlighted in yellow, followed by EST 
coding sequence starting with ATG. 
NNNNNNNNNNNNNNNNNNNTCGTGANNNNNNCGACNTTTAAATTTAATTAATCTCGACGGT
ATCGGTTAACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGT
AGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAA
AATTTTATCGATCACGAGACTAGCCTCGAGGTTTAAACATGAATTCTGAACTTGACTATTAT
GAAAAGTTTGAAGAAGTCCATGGGATTCTAATGTATAAAGATTTTGTCAAATATTGGGATAA
TGTGGAAGCGTTCCAGGCAAGACCAGATGATCTTGTCATTGCCACCTACCCTAAATCTGGTA
CAACCTGGGTTAGTGAAATTGTGTATATGATCTATAAAGAGGGTGATGTGGAAAAGTGCAA
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AGAAGATGTAATTTTTAATCGAATACCTTTCCTGGAATGCAGAAAAGAAAACCTCATGAATG
GAGTAAAACAATTAGATGAGATGAATTCTCCTAGAATTGTGAAGACTCATTTGCCACCTGAA
CTTCTTCCTGCCTCATTTTGGGAAAAGGATTGTAAGATAATCTATCTTTGCCGGAATGCAAAG
GATGTGGCTGTTTCCTTTTATTATTTCTTTCTAATGGTGGCTGGTCATCCAAATCCTGGATCCT
TTCCAGAGTTTGTGGAGAAATTCATGCAAGGACAGGTTCCTTATGGTTCCTGGTATAAACAT
GTAAAATCTTGGTGGGAAAAGGGAAAGAGTCCACGTGTACTATTTCTTTTCTACGAAGACCT
GAAAGANGATATCAGAAAAGANGTGATAAAATTGATACATTTCCTGGAAAGGAAGCCATCA
GAGGAGCTTGTGGACAGGNTTATACATCATACTTCGTTCCAAGAGATGAAGAACAATCCATC
CACAAATTACACAACACTGCCAGACGANNTNATGAACCANANNTGTCGCCCTTCATGAGAN
NGNNNTACNGNAGACTGGNAAATCACTTTNCNGTANCCCNNAATGAAAAANTNGNNNAAN
ATNATNAGCNNCNANTNNNGNNATCTACNNNNNANNNN 
 
 
pCMX-AAK-EST  SEQUENCING RESULTS FROM THE UNIVERSITY OF 
PITTSBURGH GENOMICS CORE  
Confirmation of mutant sequence (Red highlight portion is the 3’ region of SULT1E1, confirming 
the orientation is correct). 
 
NNNNNNNNNNNNNGNNNNNTGGTNNTCCAATCCTGGATCCTTTCCNGAGTTTGTGGAGAAA
TTCATGCAAGGACAGGTTCCTTATGGTTCCTGGTATAAACATGTAAAATCTTGGTGGGAAAA
GGGAAAGAGTCCACGTGTACTATTTCTTTTCTACGAAGACCTGAAAGAGGATATCAGAAAA
GAGGTGATAAAATTGATACATTTCCTGGAAAGGAAGCCATCAGAGGAGCTTGTGGACAGGA
TTATACATCATACTTCGTTCCAAGAGATGAAGAACAATCCATCCACAAATTACACAACACTG
CCAGACGAAATTATGAACCAGAAATTGTCGCCCTTCATGAGAAAG 
GCCATTACAGCCGACTGGAAAAATCACTTTACA 
  A       x      x       A    x      x      K  
 
GTAGCCCTGAATGAAAAATTTGATAAACATTATGAGCAGCAAATGAAGGAATCTACACTGA
AGTTTCGAACTGAGATCTAAGCTAGCTAGGTAGCTAGAGGATCTTTGTGAAGGAACCTTACT
TCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATA
AAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCA
ACCTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAATGAGGAAAACCTGTTTTG
CTCAGAAGAAATGCCATCTAGTGATGATGAGGCTACTGCTGACTCTCAACATTCTACTCCTC
CAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTT
GAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCTATTTACACCACAAAGGAAA
AAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATTTGATGTATAGTGCCTTGACTAGA
GATCATAATCAGCCATACCACATTTGTAGAGGTTTTACNTGCTTTAAAAAACCTCCCACACC
TCCCCCNGNANCTGAAACATAAAATGNATGN 
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 shRNA SEQUENCES FROM OPEN BIOSYSTEMS  
The targeting sequences for EST and ERα are ATGAGTCTTCACAATTCTAGG (product 
TRCN0000035880) and TTCCAGAGACTTCAGGGTGCT (product TRCN0000003299), 
respectively. Both purchased from Open Biosystems. 
 
RT- PCR PRIMER SEQUNENCES  
 
 
 
Gene Forward Reverse 
EST AGAGGAGCTTGTGGACAGGA GGCGACAATTTCTGGTTCAT
LPL TCCAAGGAAGCCTTTGAGAA TTGCTGCTTCTTTTGGCTCT
ATGL TACAGAGAGGCACTGCCCGGCT AAGGCCACGTTGGTGCAGAAGA 
SREBBP1c CTTGAGCTGCGTGGCTTCCAAC CTTGAGCTGCGTGGCTTCCAAC
GAPDH CTCAAGGGCATCCTGGGCTACA TGGTCGTTGAGGGCAATGCC
CYCLOPHILLIN TGGTCGTTGAGGGCAATGCC CACATGCTTGCCATCCAACCACT
FASN GCCGTGGACCTGATCATCAAGA ATGGTACTTGGCCTTGGGTGTGTA
SCD1 TGGGGTGAAACTTTTCAAAACAGTG CCGGGGGCTAATGTTCTTGTCATA
ACC CCGGATGCAGGAGAAGGGTGTTAT GGGTTGGCATTGTGGATTTTCTTC
aP2 CCTTTAAAAATACTGAGATTTCCTTCA GGACACCCCCATCTAAGGTT
C/EBPα AGCAGGAGAAGGCCAAGG CCCGGGTAGTCAAAGTCG
C/EPBβ GGGCCCTGAGTAATCGCTTAA ATAAACAGCAACAAGCCCG
C/EBPδ AGATGCAGCAGAAGTTGGTGGA CTGGGCAGCTGCTTGAAGAACT
HSL GAGATGTCGCTGTCAGCTGAGACA GTCCATGGGGCTCAGCTCATTT
GR TCTCTTCAGTTCCTAAGGACGG TGGAGTTTCCTTCCCTCTTGAC
ERα AGGGATGAGGGGAAATGCGTAGAA GCTGTACAGATGCTCCATGCCTTT
Erβ AGGGATGAGGGGAAATGCGTAGAA GGATCATGGCCTTGACACAGAGAT
PPARγ GGGGTACCATGGGTGAA ACTCT CTAGCTAGC CTAGTACAAGTCCT 
IGFBP4 GAGATCGAGGCCATCCAGGAAA TTTTGGCGAAGTGCTTCTGCAG
IGFBP5 GGGGTTTGCCTCAACGAAAAGA TGTGTTTGGGCCGGAAGATCTT
GPX3 ATTTCCAGCTCTTTGAGAAAGGGG GCGGATGTCGTGAACCTTCATG
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 (Above)Here we show the graph of the efficiency curve readout where the x-axis is log10  of the 
concentration of linearized plasmid( concentration shown below) and the y-axis is the 
corresponding  Ct value (average triplicate).  (Below) Linearized plasmid (p CMXpl2 hEST) 
concentration, log10 and corresponding average Ct readout. E, efficiency; % E, percent efficiency 
of primer pair.  
ng Log10 Avg CT 
10 1 4.47 
   
1 0 7.575 
   
0.1 -1 11.795 
   
0.01 -2 15.06 
   
0.001 -3 18.845 
   
0.0001 -4 22.29 
   
0.00001 -5 25.965 
   
0.000001 -6 29.02 
   
 E  % E 
 10^(-1/slope) (E-1)* 
100 
 1.909269867 90.92699 
 
y = -3.5604x + 7.9766 
R² = 0.9992 
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